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The Role of Cytotoxic Therapy with Hematopoietic
Stem Cell Transplantation in the Therapy of
Myelodysplastic Syndromes: An Evidence-Based Review
Denise M. Oliansky,1 Joseph H. Antin,2 John M. Bennett,3 H. Joachim Deeg,4
Christin Engelhardt,5 Kathleen V. Heptinstall,6 Marcos de Lima,7 Steven D. Gore,8
Ronald G. Potts,9 Lewis R. Silverman,10 Roy B. Jones,7 Philip L. McCarthy, Jr.,1 Theresa Hahn1
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of mye-
lodysplastic syndromes (MDS) in adults is presented and critically evaluated in this systematic evidence-based
review. Specific criteria were used for searching the published literature and for grading the quality and
strength of the evidence and the strength of the treatment recommendations. Treatment recommendations
based on the evidence are presented in Table 3, and were reached unanimously by a panel of MDS experts.
The identified priority areas of needed future research in MDS include: (1) the benefit of using alternative
donor sources (eg, cord blood; haploidentical family donors) for patients without matched sibling or unre-
lated donors; (2) the role and appropriate timing of allogeneic SCT in combination with hypomethylating and
immunomodulatory treatment regimens; (3) randomized trials comparing the safety and efficacy of various
novel agents for treating MDS; and (4) the influence of the various MDS treatment modalities on patient-
reported quality-of-life outcomes.
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Therapy, AdultINTRODUCTION
The American Society for Blood and Marrow
Transplantation (ASBMT) in 1999 began an initiative
to sponsor evidence-based reviews of the scientific
and medical literature for the use of hematopoietic
stem cell transplantation (SCT) in the therapy of se-
lected diseases. The steering committee convened to
oversee the projects invited an independent panel of
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doi:10.1016/j.bbmt.2008.12.003disease experts to conduct each review. Six previous
reviews have been published in Biology of Blood and
Marrow Transplantation on the use of SCT in the
therapy of: diffuse large B cell non-Hodgkin lym-
phoma [1], multiple myeloma [2], pediatric acute
lymphoblastic leukemia (ALL) [3], adult ALL [4], pe-
diatric acute myeloid leukemia (AML) [5], and adult
AML [6].
The goals of the current review are to assemble and
critically evaluate evidence regarding the role of SCT
in the therapy of myelodysplastic syndromes (MDS),
make treatment recommendations based on the avail-
able evidence, and identify areas of needed research.
LITERATURE SEARCH METHODOLOGY
PubMed and Medline, the Web sites developed by
the National Center of Biotechnology Information at
the National Library of Medicine of the National In-
stitutes of Health, were searched on January 17,
2007, using the search terms ‘‘myelodysplastic syn-
drome’’ OR ‘‘MDS’’ AND ‘‘transplant’’ limited to ‘‘hu-
man trials,’’ ‘‘English language,’’ and a publication date
of 1990 or later. Updated searches were conducted on
October 14, 2007, and April 15, 2008. Papers that were137
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patients, or were not peer-reviewed were excluded.
Also excluded were editorials, letters to the editor,
Phase I (dose escalation or dose finding) studies,
reviews, consensus conference papers, practice guide-
lines, and laboratory studies with no clinical correlates.
Abstracts and presentations at national or international
meetings were not included as evidence in this review
for reasons previously described [3]. Many of the stud-
ies evaluated for inclusion in this review presented
results for de novo MDS along with AML arising
from MDS (sAML) or AML following treatment for
other diseases (therapy-related AML) without stratify-
ing the results by de novo MDS versus AML. To be
included in this evidence-based review, studies had to
have at least 60% of the patients with de novo MDS,
or results that were stratified by disease category.
QUALITATIVE AND QUANTITATIVE
GRADING OF THE EVIDENCE
The hierarchy of evidence, including a grading
system for the quality and strength of the evidence
and strength of each treatment recommendation,
was published as an editorial policy statement in Biol-
ogy of Blood and Marrow Transplantation in 2005 [7].
Tables 1 and 2, reprinted from the policy statement,
define criteria used to grade the studies that were in-
cluded in this review, and criteria to grade the treat-
ment recommendations, respectively. Study design,
including sample size, patient selection criteria, dura-
tion of follow-up, and treatment plan also were con-
sidered in evaluating the studies. Clinical studies are
described with sufficient detail to give a concise sum-
mary of study design, sample size, eligibility criteria,
and treatment schema.
All data in the text and tables were abstracted from
the original manuscripts by the first author (D.O.), and
double checked for accuracy and clarity by 2 other au-
thors (T.H. and P.L.M.). Some articles contained in-
consistencies within the data reported; the data most
consistent with the text of the article were included
in this review. The authors D.O., T.H., and P.L.M.
take responsibility if errors remain.
TREATMENT RECOMMENDATIONS
The strength of this review is in the grading of the
strength of the evidence and quality of the study de-
signs as described in the text and outcome summary ta-
bles included in each major section. Table 3 contains
the summary of treatment recommendations made
by the MDS expert panel based on the summarized ev-
idence.FORMATOF THE REVIEW
Evidence is taken from self-described studies
which included MDS patients $15 years of age. In
each section of this review, the highest quality studies
are presented first; studies of equal quality are pre-
sented in descending order by cohort size. The design
of each study is described in the text and, unless other-
wise noted, an accompanying table in each section
presents the outcomes for each study.
TIMING OF TRANSPLANTATION
This section describes two studies examining the
impact of timing of transplantation and three studies
Table 1. Grading the Quality of Design and Strength of
Evidence
Levels of Evidence
1++ High-quality meta-analyses, systematic reviews of randomized
controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or
RCTs with a low risk of bias
12 Meta-analyses, systematic reviews of RCTs, or RCTs with a high
risk of bias
2++ High-quality systematic reviews of case-control or cohort
studies High quality case-control or cohort studies with a very
low risk of confounding, bias, or chance, and a high probability
that the relationship is causal
2+ Well-conducted case-control or cohort studies with a low risk of
confounding, bias, or chance, and a moderate probability that
the relationship is causal
22 Case-control or cohort studies with a high risk of confounding,
bias, or chance, and a significant risk that the relationship is not
causal
3 Nonanalytic studies (eg case reports, case series)
4 Expert opinion
Reprinted with permission from Harbour R, Miller J. A new system for
grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.
Table 2. Grading the Strength of the Treatment Recom-
mendation
Grades of Recommendation
A At least one meta-analysis, systematic review, or randomized
controlled trial (RCT) rated as 1++, and directly applicable to
the target population; or a systematic review of RCTs or
a body of evidence consisting principally of studies rated as 1+,
directly applicable to the target population, and
demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly
applicable to the target population, and demonstrating overall
consistency of results; or extrapolated evidence from studies
rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly
applicable to the target population and demonstrating overall
consistency of results; or extrapolated evidence from studies
rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies
rated as 2+
Reprinted with permission from Harbour R, Miller J. A new system for
grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.
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Indication for SCT
Treatment
Recommenddation
Grade*
HighestLevel of
Evidence† Reference No.h
Treatment Recommendation
Comments
Timing of Transplantation C 2+ [8,10] Early SCT is recommended for patients
with an IPSS score of INT-2 or High
risk at diagnosis, who have a suitable
donor, and meet the transplant
center’s eligibility criteria, and for
selected patients with a Low or INT-1
risk IPSS score at diagnosis who have
poor prognostic features not
included in the IPSS (ie, older age,
refractory cytopenias, etc.).
Pre-SCT Induction Chemotherapy No recommendation 2++ [11,12] In the absence of randomized controlled
trials, there are insufficient data to
make a treatment recommendation
for or against pre-SCT induction
chemotherapy. The decision to use
pre-SCT induction therapy should be
made on an individual basis.
DONOR SELECTION
Related versus Unrelated Allogeneic
SCT
No recommendation 2+ [15-20] There is no evidence of a survival
advantage based on donor relation. In
clinical practice, matched related
donor allogeneic SCT is
recommended if available. If
a matched related donor is not
available, an unrelated donor
allogeneic SCT may provide
equivalent outcomes. The published
data do not reflect the selection of
donors on the basis of molecular HLA
typing.
Related, unrelated, either, or
unspecified allogeneic SCT
B 2++ [21,22,27,32,33] There are sufficient data demonstrating
a long-term curative outcome for
related and unrelated allogeneic SCT.
Autologous versus Allogeneic SCT C 2++ [43] Based on data and expert opinion, an
HLA-matched allogeneic donor
(sibling, other family member,
unrelated individual, or cord blood)
SCT is recommended if an
appropriate donor is available. If an
allogeneic donor is not available, and
CR is achieved with induction
therapy, an autologous SCT can be
considered in the context of a clinical
trial.
TRANSPLANTATION TECHNIQUES
BMT versus PBSCT
Allogeneic BMT versus PBSCT B 1+ [47] For low-risk disease, allogeneic PBSCT
and BMT from related donors have
equivalent outcomes. Based on one
study [49], patients with high-risk
disease may have a survival advantage
with related donor allogeneic PBSCT.
No recommendation There is insufficient evidence to
recommend bone marrow versus
peripheral blood for unrelated donor
allogeneic SCT.
Autologous BMT versus PBSCT No recommendation 2+ [50] There is no evidence of a survival
advantage based on stem cell source.
Conditioning Regimen Comparisons
Reduced Intensity Conditioning versus
High Dose Regimen
No recommendation 2++ [51] There are insufficient data to make
a recommendation for an optimal
conditioning regimen intensity. A
range of dose intensities is currently
being investigated, and the optimal
approach will likely depend on disease
and patient characteristics, such as
age and comorbidities.
(Continued )
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Indication for SCT
Treatment
Recommenddation
Grade*
HighestLevel of
Evidence† Reference No.h
Treatment Recommendation
Comments
Comparison of $2 High-Dose
Regimens
No recommendation 2+ [56-58] There are insufficient data to make
a recommendation. There is no
evidence of a survival advantage with
any one high dose conditioning
regimen.
*Definitions: Grade of Recommendation (Table 2): (A) At least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++,
and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly
applicable to the target population, and demonstrating overall consistency of results; (B) A body of evidence including studies rated as 2++, directly
applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+; (C)
A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or ex-
trapolated evidence from studies rated as 2++; (D) Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+.
†Definitions: Levels of Evidence (Table 1): 1++ High-quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with
a very low risk of bias; 1+ Well-conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; 12 Meta-analyses, systematic
reviews of RCTs, or RCTs with a high risk of bias; 2++ High quality systematic reviews of case-control or cohort studies; or high quality case-control or
cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal; 2+Well conducted case control or
cohort studies with a low risk of confounding, bias, or chance, and a moderate probability that the relationship is causal; 22 Case-control or cohort
studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal; 3 Nonanalytic studies (eg, case reports,
case series); 4 Expert opinion.
hThe references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence de-
scribed in the review.
SCT indicates stem cell transplantation; PBSCT, peripheral blood stem cell transplantation; BMT, bone marrow transplantation; HLA, human leukocyte
antigen; CR, complete remission; IPSS, International Prognostic Scoring System; INT, intermediate.examining the effect of pretransplantation induction
chemotherapy on patient outcomes in the treatment
of MDS. Table 4 presents a summary of the patient
outcomes from these studies.
Cutler et al. [8] presented the results of a study
using a Markov decision model to determine the op-
timal timing of human leukocyte antigen- (HLA)
identical sibling donor allogeneic transplantation to
treat MDS, dependent upon the patients’ Interna-
tional Prognostic Scoring System (IPSS) scores [9].
Included were three cohorts of adults (18-60 years)
with MDS whose data were derived from prospec-
tively collected databases. A nontransplantation co-
hort (n 5 184) from the International MDS Risk
Analysis Workshop (IMRAW) was compared with
a transplantation cohort (n 5 260) that combined pa-
tients from the International Bone Marrow Trans-
plant Registry (IBMTR) and from the Fred
Hutchinson Cancer Research Center (FHCRC).
The transplantation cohort (IBMTR 1 FHCRC)
was younger and more likely to have more advanced
MDS than the nontransplantation (IMRAW) cohort.
The treatment regimen(s) for the nontransplantation
cohort (IMRAW) was supportive care only. The
transplantation cohort received HLA-identical sib-
ling donor allogeneic SCT following unspecified ab-
lative conditioning regimens. Median follow-up was
35.4 months and 11.4 months for the nontransplanta-
tion and transplantation cohorts, respectively. Me-
dian survival times were significantly influenced by
IPSS score at the time of diagnosis. Figure 1 illus-trates the impact of timing of SCT on life expectancy
by IPSS risk group. For low- and intermediate-1-risk
MDS, maximal life expectancy was associated with
delayed allogeneic SCT. For Intermediate-2- and
high-risk MDS, immediate allogeneic SCT was asso-
ciated with maximal life expectancy.
Runde et al. [10] examined the impact of early
HLA-identical sibling donor allogeneic bone marrow
transplantation (BMT) in 131 adult (92% $16 years)
patients with MDS (86%) or sAML reported to the
Chronic LeukemiaWorking Party (CLWP) of the Eu-
ropean Group for Blood and Marrow Transplantation
(EBMT). Median disease duration was 7 months, and
Figure 1. Net benefit or loss of overall discounted life expectancy for
the 4 IPSS risk groups shown above and below the x-axis. A net benefit
for delaying transplantation is noted for low and int-1 risk group,
whereas any delay in the time to transplantation is associated with
a loss in survivorship in the higher risk groups. (Reprinted with permis-
sion, Cutler et al. 2004.)
ction
(n)
(Interval)
% TRM
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
Not stated Not stated Not stated
See Figure 1
(5-year %TRM) (5-year %DFS) (5-year %OS)
29% ± 10%
48% ± 7%
51% ± 9%
38% ± 10%
25% ± 7%
42% ± 9%
54% ± 9%
27% ± 7%
43% ± 9%
n
)
3)
)
(P 5 .05) (P 5 .03) (P 5 .03)
(Continued)
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
5
:1
3
7
-1
7
2
,
2
0
0
9
1
4
1
R
o
le
o
f
C
yto
x
ic
T
h
e
ra
p
y
w
ith
H
S
C
T
in
th
e
T
h
e
ra
p
y
o
f
M
D
STable 4. Comparison of Patient Characteristics and Outcomes from Studies Included in the Timing of Transplantation Se
Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or
Subtype
(at Dx Unless
Otherwise Stated) Median Follow-up Study Groups
TIMING OF TRANSPLANTATION
[8] 2+
IMRAW—No SCT
n 5 184
Age range: 18-60
Median age 49.8
years
IMRAW
(n 5 184)
Not stated
IMRAW
RA 51.6%
RARS 16.9%
RAEB 25.0%
RAEBt 6.5%
IMRAW
35.4 months
1990-1999
IBMTR—SCT
Multicenter
n 5 193
Age range: 18-59
Median age 39.4
years
IBMTR and FHCRC
(n 5 260)
Unspecified ablative
conditioning
regimens
IBMTR
RA 30.57%
RARS 2.07%
RAEB 28.5%
RAEBt 34.72%
Unknown 4.15%
IBMTR and
FHCRC11.4
months
1990-1999
FHCRC—SCT
Single center
n 5 67
Age range: 20-60
Median age 45.6
years
FHCRC
RA 38.81%
RARS 4.48%
RAEB 37.31%
RAEBt 17.91%
Unknown 1.49%
[10] 2+ 1983-1994
EBMT
Multicenter (44)
n 5 131
No IC chemo
Conditioning
varied by center;
most TBI-
containing or
chemo alone
RA/RARS 35%
RAEB 27%
RAEBt 21%
CMML 3%
sAML 14%
27 months
Age range: 2-55
Median age 33 years
92% >16 years
86% MDS
HLA-identical
sibling allo-SCT
Disease duratio
#3 months (36
4-12 months (5
>12 months (39
val)
M
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
ated (4-year %DFS) (4-year %OS)
17.3% ± 3.7% 25.5% ± 4.6%
28.9 ± 4.85% 34.4% ± 5.1%
(P5.017) (P5.16)
tated,
RM)
Not stated (5-year %OS)
t
ed
58.2%
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(P 5 .11)
%
%
%
54%
20%
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Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or
Subtype
(at Dx Unless
Otherwise Stated) Median Follow-up Study Groups (n)
(Inter
% TR
Pretransplantation Induction Chemotherapy
[11] 2++
1990-1997
MDACC
Chemo-only
Single center
n 5 215
CR1
n 5 135
Not st
Age range: 15-60
Median age not
stated
MDACC
HD Ara-C
Alone
+ Flu + IDR
+ Flu
+ IDR
+ Topotecan
+ DNR
MDACC
RAEB 17.7%
RAEBt 43.4%
sAML 39%
MDACC
3.0 years
MDACC
Chemo only (135)
1992-1997
EORTC
Chemo + SCT
Multicenter (35)
n5184
CR1 n5100
EORTC
IC Chemo + SCT
(Auto or Allo)
(100)
67% MDS
EORTC
Induction:
SD Ara-C + IDR
+ VP-16
Consolidation:
Ara-C + MITO
Transplant
Regimen:
Cy + f-TBI
OrBu + Cy
EORTC
RA 3.8%
RARS .5%
RAEB 29.4%
RAEBt 32.6%
(CMML 8.7%, not
included in analysis)
sAML 25%
EORTC
3.6 years
(ITT analysis)
[12] 2++ 1991-2001
JSHCT
Multicenter
n 5 283
IC Chemo
not specified
IC Group
RA 15.5%
RAEB 15.5%
RAEBt 29%
CMML 10%
sAML 30%
36.5 months (Not s
%T
Age range: 16-65
Median age 41 years
TBI-based or
chemo-based
conditioning
regimens
RA + RAEB
Total n 5 119
IC Group— CR
IC Group— NR
No IC Group
No
stat
76% MDS HLA-identical
sibling
allo-SCT
No IC Group
RA 34%
RAEB 30.5%
RAEBt 16%
CMML 6%
sAML 13.5%
RAEBt + sAML
Total n5139
IC Group - CR
IC Group - NR
No IC Group
17.8
48.9
18.8
(P5.0
(3-year %TRM) (3-year %RFS) Not stated
3) 34% 13%
p (92) 44% 26%
(P not signif) (P 5 .26)
(Not stated,
%TRM)
(2-year %DFS) Not stated
or Not stated 60% ± 13%
60% Not stated
100%
p
22%
17%
20%
39%
58%±19%
74%±14%
50%±15%
18%±11%
therapy; CR, complete remission; DX, diagnosis; RA, refractory anemia;
in transformation; CMML, chronic myelomonocytic leukemia; sAML, sec-
nization of Research and Treatment of Cancer; MDACC, M.D. Anderson
, Japan Society for Hematopoietic Cell Transplantation; TRM, treatment-
fidence interval; HD, high dose; SD, standard dose; t-Bu, targeted busulfan;
ide; MITO, Mitoxantrone; DNR, Daunorubicin.
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S[13] 2+ 1992-2002
Single center
n 5 125
IC: ARA-C +
anthracycline
IC Group
RAEB 9%
RAEBt 18%
tAML 73%
Not stated
IC Group
Age range: 2-64
Median age 45 years
Conditioning
Regimen:
Bu+TBI or
t-Bu+Cy
No IC Group
RAEB 67%
RAEBt 24%
tAML 9%
IC Group (3
No IC Group
Age range: 3-66
Median age 50 years
HLA-matched
related
or unrelated
donor allo-SCT
No IC Grou
74% MDS
[14] 2+ 1980-1988
Multicenter (21)
n 5 78
Conditioning
Regimen:
TBI+chemo or
Bu+Cy
IC Group
RAEB 12%
RAEBt 29%
CMML 3%
sAML 56%
27 months
Age range: 2-52
Median age 32 years
HLA-matched
sibling,
syngeneic, or
mismatched
sibling allo-SCT
No IC Group
RA/RARS 20%
RAEB 27%
RAEBt 23%
sAML 30%
IC Group
In CR (sAML
RAEBt) (16)
70% MDS
Partial (10)
Resistant (8)
No IC Grou
RA/RAS (9)
RAEB (12)
RAEBt (10)
sAML (13)
*Quality and strength of evidence definitions are listed in Table 1.
†Allo indicates allogeneic; Chemo, chemotherapy; BMT, bone marrow transplantation; SCT, stem cell transplantation; IC, induction chemo
RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEBt, refractory anemia with excess blasts
ondary acute myeloid leukemia; tAML, therapy-related AML; IMRAW, International MDS Risk Analysis Workshop; EORTC, European Orga
Cancer Center; EBMT, European Group for Blood and Marrow Transplantation; FHCRC, Fred Hutchison Cancer Research Center; JSHCT
related mortality; DFS, disease-free survival; EFS, event-free survival; RFS, relapse-free survival; P, probability; OS, overall survival; CI, 95% con
Ara-C, Cytarabine; Cy, cyclophosphamide; Bu, Busulfan; TBI, total-body irradiation; f-TBI, fractionated TBI; IDR, Idarubicin; VP-16, etopoc
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by the time of BMT. No patients received induction
chemotherapy prior to BMT. Conditioning regimens
varied by center, butmost patients (70%) received a to-
tal-body irradiation (TBI)-containing regimen.
Twelve percent of patients received T cell-depleted
bone marrow. In multivariate analysis, French-Ameri-
can-British (FAB) classification and disease duration
significantly influenced overall survival (OS) and dis-
ease-free survival (DFS).
Pretransplantation Induction Chemotherapy
Oosterveld et al. [11] reported the results of a retro-
spective cohort study of 399 adults (15-60 years) with
MDS (67%) or sAML treated either at the M.D. An-
derson Cancer Center (MDACC, n5 215) or enrolled
in the multicenter European Organization for Re-
search andTreatment of Cancer (EORTC) 06921 trial
(n 5 184), comparing the effectiveness of chemother-
apy only versus induction chemotherapy 1 SCT. The
MDACC cohort (MDS n5 131 [61%], sAML n5 84)
was older, more likely to have poor performance sta-
tus, and included more sAML patients, whereas the
EORTC cohort (MDS n 5 138 [75%], sAML n 5
46) had a higher proportion of MDS patients. Patients
at MDACC received chemotherapy only, consisting of
various high-dose cytarabine-containing regimens for
remission induction followed by reduced doses for 6
to 12 months. Of 215 patients, 135 achieved complete
remission (CR). The EORTC patients (Chemo 1
SCT cohort) received standard dose cytarabine1 idar-
ubicin 1 etoposide for remission induction (100 pa-
tients achieved CR), followed by one consolidation
course of cytarabine 1 mitoxantrone, then an alloge-
neic SCT (n 5 28, of 39 patients who achieved CR
and had a sibling donor) or autologous SCT (n 5 36,
of 61 patients in CRwithout a sibling donor) after con-
ditioning with cyclophosphamide 1 fractionated TBI
or busulfan 1 cyclophosphamide. One patient re-
ceived an HLA-matched unrelated donor allogeneic
SCT. Reasons for not receiving a transplant in CR in-
cluded early relapse (n5 26), toxicity or treatment re-
fusal (n5 7), or death (n5 2). In multivariate analysis,
cytogenetics, white blood cell (WBC) count at diagno-
sis, age, platelet count, and hemoglobin significantly
influenced OS, whereas treatment protocol (EORTC
versus MDACC), cytogenetics, and hemoglobin sig-
nificantly influenced DFS.
Nakai et al. [12] compared the outcomes of 283
adult (16-65 years) patients with MDS (76%) or
sAML who received (n 5 188) or did not receive
(n 5 95) induction chemotherapy prior to HLA-iden-
tical sibling donor allogeneic SCT and were registered
with the Japan Society for Hematopoietic Cell Trans-
plantation (JSHCT). There were significantly more
patients with advanced disease and poor karyotype inthe group that received induction chemotherapy
(chemo group) than in the no chemo group. Of those
patients in the chemo group, 81 (43%) underwent allo-
geneic SCT inCR. The conditioning regimen for allo-
geneic SCT consisted of a TBI-based (n 5 173) or
chemotherapy-based regimen (n 5 110). Stem cell
sources were bone marrow (n 5 218) or peripheral
blood (n 5 65). Median time from diagnosis to SCT
was 8 months. Survival outcomes were stratified by
FAB because of the significantly higher proportion of
RAEB-t and AML patients in the chemo group. In
multivariate analysis, FAB, presence or absence of in-
duction chemotherapy, and karyotype significantly
influenced OS.
Scott et al. [13] presented the results of 125 adult
(median age, 47 years) patients with advanced MDS
(74%) or therapy-related AML who underwent an
HLA-identical related or unrelated donor allogeneic
SCT, comparing the outcomes of patients who re-
ceived induction chemotherapy 1 to 6 months (me-
dian, 2 months) before SCT (n 5 33) with those
who did not receive induction chemotherapy (n 5
92). Median disease duration was 6 months for both
groups. Most patients in the induction chemotherapy
group received cytarabine-based therapy (82%). Allo-
geneic SCT conditioning regimens included busulfan
1 cyclophosphamide (n 5 76) or busulfan 1 TBI
(n 5 49). Stem cell sources were bone marrow (n 5
80) or peripheral blood (n 5 45) from HLA-matched
related (n 5 65) or unrelated donors (n 5 60). Mul-
tivariate analysis of the impact of patient and treat-
ment variables on survival outcomes was not
performed.
De Witte et al. [14] reported the outcomes of 78
adult (median age, 32 years) patients with MDS
(70%) or sAML who underwent an HLA-matched
(n5 74), syngeneic (n5 3), or mismatched (n5 1) re-
lated allogeneic SCT, comparing the outcomes of pa-
tients who received induction chemotherapy and
were inCR (n5 16), thosewho received induction che-
motherapy but were not in CR (n5 18), and those who
did not receive induction chemotherapy prior to allo-
geneic SCT (n 5 44). Conditioning regimens varied
by center, but the majority (89%) received TBI1 che-
motherapy (unspecified). Median time from diagnosis
to allogeneic SCT was 7 months. Thirteen patients
with sAMLwithout precedingMDSwere transplanted
at amedianof 4months after diagnosis.Outcomeswere
presented according to IPSS and disease status at SCT.
DONOR SELECTION
This section presents studies that compare patient
outcomes using allogeneic and autologous SCT in the
treatment of MDS. Table 5 presents a summary of the
patient outcomes from these studies.
Interval)
% TRM
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
ear %TRM) (3-year %RFS) Not stated
28% 56%
30% 59%
(P Not Signif)
ear %TRM) (1-year %DFS) (1-year %OS)
5% 61% 73%
21% 59%
71%
(P Not Signif) (P Not Signif)
ear %TRM) (3-year %RFS) (3-year %OS)
35% 30% 26% for all patients
55% 25%
(P Not Signif)
ear %TRM) Not stated (3-year %OS)
31% 48%
51% 30%
(P 5 .19)
ear %TRM) (2-year %DFS)
51.2%
(CI 43.3%-58.5%)
(all patients)
(2-year %OS)
31.6% 47.4%
37.5% 58.3%
(P 5 .64)
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STable 5. Summary of Patient Characteristics and Outcomes from Studies Included in the Donor Selection Section
Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated)
Median
Follow-up
Study
Groups (n)
(
ALLOGENEIC SCT
Related versus Unrelated Allogeneic SCT
[15] 2+ 1993-2000
Single center
n 5 109
Bu + Cy RA/RARS 63%
RAEB 22%
RAEBt 9%
CMML 6%
Not stated (3-y
Related (45)
Age range: 6-66
Median age, 46 years
Unrelated (64)
[16] 2+ Study dates not stated
Single center
n 5 62
Induction Chemo:
Flu +Ara-C+IDR-
containing regimens
RA/RARS 26%
RAEB-I 15%
RAEB-II 16%
CMML 6%
AML 37%
473 days (1-y
Age range: 22-70
Median age, 53 years
RIC
Flu + Bu +
Alemtuzumab
Related (24)
63% MDS
Unrelated (38)
[17] 2+ 1994-1999
Single center
n 5 60
RIC
Bu + f-TBI
RAEB 35%
RAEBt 27%
CMML 13%
sAML 25%
54 months (3-y
Related (20)Age range: 12-62
Median age, 40 years Unrelated (40)
75% MDS
[18] 2+ 1995-2002
Single center
n 5 51
RIC
Cy + 550 cGy TBI
(At SCT)
RA 23.5%
RAEB 25.5%
RAEBt 18%
sAML 33%
3.7 years (3-y
Related (21)
Age range: 19-70
Median age, 44 years
Unrelated (30)
66% MDS
[19] 2+ 2000-2004
Single center
n 5 43
RIC
Flu+Mel
RA 19%
RARS 2%
RAEB 30%
RAEBt 14%
sAML 35%
38 months (2-y
Related (19)
Age range: 30-71
Median age, 58 years
Unrelated (24)
65% MDS
(Interval)
% TRM
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
-year %TRM) (3-year % DFS) (3-year %OS)
12% 31% (CI 9%-53%) 45% (CI 19%-71%)
45% 25% (CI 4%-47%) 51% (CI 29%-73%)
(P 5 .03) (P not signif) (P not signif)
-year %TRM) (5-year %DFS) (7-year %OS)
(CI 13%-55%) 34% (CI 14%-54%) 36% (CI 15%-57%)
(CI 36%-41%) 28% (CI 25%-31%) 32% (CI 29%-35%)
(P 5 .05) (P 5 .20) (P 5 .09)
-year %TRM) (4-year %DFS) (4-year %OS)
Overall MDS only MDS only
(CI 14%-32%) 49% (CI 31%-67%) 49% (CI 31%-76%)
-year %TRM) (3-year %DFS) (3-year %OS)
(CI 32%-42%) 40% (CI 36%-45%) 42% (CI 37%-47%)
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l.Table 5. (Continued)
Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated)
Median
Follow-up
Study
Groups (n)
[20] 2+ Study dates not stated
Multicenter (8)
n 5 37
RIC
Flu + Bu ± ATG
RA 21%
RAEB 16%
RAEBt 35%
CMML 8%
sAML 20%
20 months (3
Related (19)
Age range: 23-72
Median age, 55 years
Unrelated (18)
81% MDS
Related Allogeneic SCT
[21] 2++ 1978-2001
EBMT
Multicenter
n 5 1482
TBI- or non-TBI-
containing regimens
Twins
RA/RARS 33%
RAEB/CMML 20%
RAEBt/sAML 47%
Unclassified
Not stated (5
Twins
Age range: 6-71
Mean age, 43.5 years
Syngeneic or HLA-
identical sibling allo-
SCT
Twins (38) 27%
HLA-Identical Sibs
Age range: 1-69
Mean age, 37.3 years
Sibs
RA/RARS 13%
RAEB/CMML 25.5%
RAEBt/sAML 61.5%
Siblings (1444) 38%
[22] 2++ 1998-2005
Multicenter (6)
n 5 93
MDS only n 5 34
RIC
Bu + Flu
MDS subtypes not
stated
43 monthss (4
HLA-identical sibling
allo- PBSCT
(BMT in 1 patient)
All patients:
Age range: 21-70
Median age, 53 years
20%
[23] 2+ 1989-1997
IBMTR
Multicenter (143)
n 5 452
Bu + Cy
Bu + Cy + TBI
Bu + Cy + other
Cy + TBI
Cy + TBI + other
TBI + other (not Cy)
Various
RA 27%
RARS 4%
RAEB 30%
RAEBt 30%
CMML 9%
49 months (3
Age range: 2-64
Median age 38 years
86% >18 years HLA-identical sibling
allo-SCT
37%
(7-year %TRM) (7-year %EFS) (7-year %OS)
39% ± 7% 39% ± 7% 32% ± 6%
(3-year %TRM) Not stated (3-year %OS)
43% Overall MDS 36%
Overall 34%
(2-year %TRM) (2-year %DFS) (2-years %OS)
50% 38% (CI 24%-55%) 45% (CI 30%-61%)
(3-year %TRM) (3-year %DFS) (3-year %OS)
30% (CI 24%-36%) 41% (CI 35%-47%) 43% (CI 37%-49%)
(2-year %TRM) (4-year %DFS) (4-year %OS)
54% (CI 53%-61%) 26% (CI 22%-30%) 26% (CI 22%-30%)
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S[24] 2+ 1982-1991
FBMTR
Multicenter (24)
n 5 71
TBI + Cy
Bu + Cy
Various other ± TBI
RA 23%
RAEB 38%
RAEBt 39%
6 years
Age range: 5-55
Median age, 37 years
93% >15 years
HLA-identical sibling
allo-SCT
[25] 2+ 1979-2002
Single center
n 5 52
Bu + Cy
Cy + TBI
Bu + Flu
Cy
RA 25%
RAEB 32%
RAEBt 8%
CMML 2%
4.6 years
Age range: 60-68
Median age, 62.8 years
CML 15%
AML 12%
Other 6%
67% MDS
HLA-matched sibling
allo-SCT
[26] 2+ 1986-1991
2 centers
n 5 38
Bu + Cy Hyploplastic MDS 13%
RAEB or RAEBt 47%
MDS w/ marrow
fibrosis 19%
sMDS or AML 21%
Not stated
Age range: 5-55
Median age, 35 years
50% > 35 years
HLA-identical sibling
allo-BMT
79% MDS
Unrelated Allogeneic SCT
[27] 2++ 1999-2004
Single center
n 5 75
RIC
Flu + Bu +
Alemtuzumab
RCMD 39%
RAEB I/II 20%
CMML 9%
sAML 32%
1038.5 days
Age range: 24-68
Median age, 52 years
HLA-matched or
mismatched
unrelated allo-SCT
68% MDS
[28] 2+ 1988-1998
NMDP
Multicenter (87)
n 5 510
f-TBI + Cy ± other
Bu + Cy ± other
TBI + Bu + Cy
Other
RA 37%
RARS 2%
RAEB 32%
RAEBt 21%
CMML 4%
Myelofibrotic-MDS 2%
Unknown 2%
24 months
Age range: 1-62
Median age, 38 years
72% >20 years
HLA-matched or
mismatched
unrelated allo- SCT
(Interval)
% TRM
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
ear %TRM) (2-year %DFS) (2-year %OS)
58% 28% 28%
ear %TRM) (2-year %DFS) (2-year %OS)
48% 38% 40%
ot stated (2-year %DFS) (2-year %OS)
MDS only MDS only
18% ± 14% 29% ± 15%
ear %TRM) (2-year %EFS) (2-year %OS)
DS only
51%
MDS only
15%
MDS only
18%
Overall
(CI 36%-62%)
Overall
28% (CI 18%-39%)
Overall
30% (CI 19%-40%)
1
4
8
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
5
:1
3
7
-1
7
2
,
2
0
0
9
D
.
M
.
O
lia
n
sky
e
t
a
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Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated)
Median
Follow-up
Study
Groups (n)
[29] 2+ 1986-1996
EBMT
Multicenter (49)
n 5 118
Chemo (not
specified) + TBI
Chemo +
serotherapy
RA/RARS 20%
RAEB 22%
RAEBt 29%
CMML 10%
sAML 19%
Not stated (2-y
Age range: <1–53
Median age, 24 years
61% >18 years
81% MDS
HLA-matched or
mismatched
unrelated allo-
SCT
[30] 2+ 1987-1993
2 centers
n 5 52
Bu + CyBu + Cy
+ TBI
(at BMT)
RA 39%
RAEB/CMML 19%
RAEBt 17%
sAML 25%
Not stated (2-y
Age range: 1-53
Median age, 32.6 years
72% >20 years
HLA-matched or
mismatched
unrelated allo-
SCT
75% MDS
[31] 2+ 1987-1990
NMDP
Multicenter (28)
Total n 5 462
MDS only n 5 32 (7%)
Not stated MDS 7% Not stated N
HLA-matched or
mismatched
unrelated allo- SCT
MDS age range: 1.4-
45.5
MDS Median age, 24.3
years
Related or Unrelated (or Unspecified Donor Relation) Allogeneic SCT
[32] 2++ 1980-1998
FBMTR
Multicenter
n 5 70
Bu + Cy
Cy + TBI
Cy + Mel
Other ± TBI
Other, no TBI
tMDS 44%
tAML 56%
7.9 years (2-y
Age range: 16-55
Median age,
37 years
M
44% MDS HLA-matched or
mismatched related
or unrelated allo-
SCT 49%
(Not stated, %TRM) (4-year %RFS) (4-year %OS)
34% 41% 41%
(5-year %TRM) (5-year %DFS) Not stated
40% 41%
(7-year %TRM) (7-year %EFS) Not stated
50% (CI 37%-64%) 29% (CI 16-43%)
(3-year %TRM)
43%
(3-year %DFS) Not stated
45% (CI 32%-59%)
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S[33] 2++ 1998-2004
Single center
n 5 43
Bu + Cy
Bu + Cy + TBI
Bu + f-TBI
Bu + TBI + amifostine
Flu +Bu
Cy + TBI
Bu + Cy + ATG
Cy + ATG + TBI
Flu + TBI
TBI + iodine + antibody
CMML:
Proliferative‡ 37%
Nonprolif. 63%
2096 days
Age range: 1-66
Median age, 48 years
HLA-matched or
mismatched related
or unrelated allo-
SCT
[35] 2+ 1981-1990
Single center
n 5 93
Cy + TBI
Bu + Cy
RA 43%
RAEB 33%
RAEBt 15%
CMML 2%
Other 7%
6.1 years
Age range: 1-60
Median age, 30 years
75% >20 years
HLA-matched related
or unrelated allo-
SCT
[37] 2+ 1986-1996
Single center
n 5 60
Bu + Cy
Cy + f-TBI
Bu + Cy + other
Cy + TBI + other
RA/RARS 23%
RAEB 18%
RAEBt 39%
sAML 20%
70 months
Age range: 15-55
Median age, 40 years
80% MDS
HLA-matched or
mismatched related
or unrelated allo-
SCT
[38] 2+ 1981-1988
Single center
n 5 59
Cy + TBI
Bu + Cy
RA 29%
RAEB 41%
RAEBt 10%
AA 10%
Myelofibrosis 7%
Unclassified 3%
Not stated
Age range: 4-54
Median age, 29 years
80% >20 years
83% MDS
HLA-matched or
mismatched related
or unrelated allo-
SCT
)
(Interval)
% TRM
(Interval)
% DFS/RFS/EFS
(Significance)
(Interval)
% OS
(Significance)
(2-year %TRM) (2-year %RFS) (2-year %OS)
39% 42% 46%
(1-year %TRM) (5-year %DFS) (5-year %OS)
55% (CI 36%-68%) 18% (CI 13%-23%) 21% (CI 15%-27%)
(Not stated, %TRM) (Not stated, %DFS) (Not stated, %OS)
24% 34.9% 42.4%
(Not stated, %TRM) (2-year %DFS) Not stated
40% 39% (CI 22%-56%)
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Reference No.
Quality and
Strength
of Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated)
Median
Follow-up
Study
Groups (n
[39] 2+ 1989-1998
Single center
n 5 50
Cy + f-TBI
Cy + f-TBI w/ lung
shield
Bu + f-TBI
Bu + Cy
t-Bu + Cy
RA 26%
RAEB 38%
RAEBt/sAML 32%
CMML 4%
2.2 years
Age range: 55-66
Median age,
58.8 years
68% MDS
HLA-matched or
mismatched related
or unrelated allo-
SCT
[40] 2+ 1988-2000
EBMT
Multicenter (43)
n 5 50
TBI-containing
regimen
Chemo (unspecified)
CMML 100% 40 months
Age range: 19-61
Median age,
44 years
HLA-matched related
or HLA-matched or
mismatched
unrelated allo- SCT
[41] 2+ 2000-2001
2 Centers
n 5 42
Flu + Bu RA 14%
RAEB 26%
RAEBt 9.5%
CMML 12%
Treated sAML 24%
Untreated sAML 5%
CML 9.5%
18 months
Age range: 12-65
Median age, 52 years
HLA-matched or
mismatched related
or unrelated allo-
SCT62% MDS
[42] 2+ 1986-1994
Single center
n 5 35
Cy + TBI ± IDAOther RA 37%
RAEB 20%
RAEBt 31%
CMML 3%
sAML 9%
20 months
Age range: 23-60
Median age, 41 years
HLA-matched related
or unrelated allo-
BMT
91% MDS
Not stated (4-year %EFS) (4-year %OS)
r (Auto) (65) 21.5% ± 5.3% 39.0% ± 6.5%
llo) (52) 23.1% ± 6.2% 33.3% ± 6.7%
(P5.66) (P 5 .18)
(3-year %TRM) (3-year %DFS) (3-year %OS)
3)
R)
29% 30% 32%
(885)
ed family
1)
8)
43% 36% 41%
66%
58%
28%
25%
31%
26%
(P not stated) (P not stated) (P not stated)
; PBSCT, peripheral blood SCT; DX, Diagnosis; MDS, myelodysplastic syndromes;
ry anemia with excess blasts in transformation; CMML, chronic myelomonocytic
AML; EBMT, European Group for Blood and Marrow Transplantation; EORTC,
h Bone Marrow Transplantation Registry; NMDP, National Marrow Donor Pro-
lapse-free survival; signif, significance (Probability); OS, overall survival; CI, 95%
, Idarubicin; MITO, Mitoxantrone; ATG, antithymocyte globulin; Cy, Cyclophos-
, matched related donor; MUD, mtched unrelated donor;
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[43] 2++ 1992-1997
EORTC
Multicenter (35)
n 5 184
Eligible for analysis
n 5 159
HLA-Typed n 5 128
Included in analysis
n 5 117
Induction:
SD Ara-C + IDR +
VP-16
No Donor (Auto)
RA/RARS 6.2%
RAEB 29.2%
RAEBt 40.0%
CMML 6.2%
sAML 18.5%
3.6 years
Consolidation:
Ara-C + MITO
No Dono
Age range 16-60
Median age, 47 years
Conditioning
for SCT:
Cy + f-TBI or
Bu + Cy Donor (Allo)
RA/RARS 3.8%
RAEB 30.8%
RAEBt 30.8%
CMML 7.7%
sAML 26.95%
Donor (A
75% (of 184) MDS
[45] 2+ 1983-1998
EBMT
Multicenter (193)
n 5 1347
Not Stated Not Stated Not Stated
Auto SCT
72% >20 years
Auto (17
(126 in C
MRD-Sib
82% >20 years Allo:
MRD-Sib
Mismatch
donor (9
MUD (19
Mismatched Family
Donor
60% >20 years
MUD
58% >20 years
>60% MDS
*Quality and strength of evidence definitions are listed in Table 1.
†Allo indicates allogeneic; Auto, autologous; chemo, chemotherapy; BMT, bonemarrow transplantation; SCT, stem cell transplantation
RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEBt, refracto
leukemia; sMDS, secondary MDS; tMDS, treatment-related MDS; sAML, secondary acute myeloid leukemia; tAML, treatment-related
European Organization of Research and Treatment of Cancer; IBMTR, International Bone Marrow Transplant Registry; FBMTR, Frenc
gram; HLA, human leukocyte antigen; TRM, treatment-related mortality; DFS, disease-free survival; EFS, event-free survival; RFS, re
confidence interval; P, probability; RIC, reduced-intensity conditioning; SD, standard dose; Ara-C, Cytarabine; Flu, Fludarabine; IDR
phamide; Bu, Busulfan; t-Bu, targeted Bu; Mel, Melphalan; VP-16, etoposide; TBI, total-body irradiation; f-TBI, fractionated TBI; MRD
‡Proliferative CMML 5WBC count >13  109/L; Nonproliferative CMML 5WBC count #13  109/L.
152 Biol Blood Marrow Transplant 15:137-172, 2009D. M. Oliansky et al.Allogeneic SCT
Related Versus Unrelated
Deeg et al. [15] reported the outcomes of 109 adult
(median age, 46 years) patients with MDS who re-
ceived HLA-matched or partially mismatched related
(n 5 45) or unrelated (n 5 64) allogeneic SCT after
conditioning with busulfan1 cyclophosphamide. Eti-
ology of MDS included de novo (n 5 78), therapy-re-
lated (n 5 14), or antecedent hematological disorder
(n 5 17). The median interval from diagnosis to
SCTwas 10months. Stem cell sources were bone mar-
row (n5 81) or peripheral blood (n5 28). In multivar-
iate analysis, no patient or treatment variables were
significantly associated with relapse-free survival
(RFS). Figure 2 presents DFS by donor relation.
Ho et al. [16] reported the results of 62 adult (22-70
years) patients with MDS (63%) or AML with multili-
neage dysplasia who received a reduced intensity con-
ditioning regimen of fludarabine 1 busulfan 1
alemtuzumab prior to allogeneic SCT from an HLA-
matched sibling (n 5 24) or unrelated donor (n 5
38). Forty-six patients received at least one course of in-
duction chemotherapy. Stem cell sources were bone
marrow (n5 21) or peripheral blood (n5 41). Median
time from diagnosis to SCT was 15 months. Multivar-
iate analysis of the impact of patient and treatment vari-
ables on survival outcomes was not performed.
Jurado et al. [17] presented the results of 60 adult
(12-62 years) patients with advanced MDS (75%) or
sAML who received reduced intensity conditioning
with busulfan 1 fractionated TBI prior to allogeneic
SCT from HLA-matched or partially mismatched re-
lated (n 5 20) or unrelated (n 5 40) donors. Stem cell
sources were bone marrow (n 5 58) or peripheral
blood (n 5 2). The median interval from diagnosis to
allogeneic SCT for all patients was 12 months; 6.6
months for related, and 14.7 months for unrelated al-
logeneic SCT. In multivariate analysis, cytogenetic
risk and disease duration influenced RFS.
Figure 2. DFS among recipients of the HLA-identical related, HLA-
identical unrelated, and HLA-nonidentical (related or unrelated) trans-
plants. The 1 indicates censored patient. (Reprinted with permission,
Deeg et al., 2002.)Hallemeier et al. [18] reported the results of a study
of 51 adult (.18 years) patients with MDS (66%) or
sAML who received reduced intensity conditioning
with cyclophosphamide 1 550 cGy TBI prior to
HLA-identical sibling (n 5 21) or HLA-matched or
partially mismatched unrelated (n 5 30) allogeneic
SCT. Stem cell sources were peripheral blood for re-
lated SCT and bone marrow for unrelated allogeneic
SCT. Of the 17 patients with sAML, 15 received in-
duction chemotherapy and two did not. Median time
from diagnosis to SCT was 7 months. In multivariate
analysis, survival outcome was influenced by FAB at
SCT, sex, transplant type (related versus unrelated),
and time from diagnosis to SCT.
Nakamura et al. [19] reported the outcomes of 43
adult (30-71 years) patients with MDS (65%) or
sAML who underwent an allogeneic SCT from an
HLA-identical sibling (n 5 19) or HLA-matched un-
related (n 5 24) donor, following reduced intensity
conditioning with fludarabine 1 melphalan. Four of
28 MDS patients and 13 of 15 sAML patients received
induction chemotherapy. At the time of allogeneic
SCT, 34 (79%) patients had persistent MDS or
AML. Stem cell sources were bone marrow (n 5 20)
or peripheral blood (n5 23). Median times from diag-
nosis to SCT were 2.46 and 7.21 months for patients
receiving a sibling or unrelated donor allogeneic
SCT, respectively. Multivariate analysis of the impact
of patient and treatment variables on survival out-
comes was not performed.
Kro¨ger et al. [20] presented the outcomes of 37
adult (23-72 years) patients with MDS (81%) or
sAML who received an HLA-matched related (n 5
19) or HLA-matched unrelated (n 5 18) allogeneic
SCT following a reduced intensity conditioning regi-
men consisting of fludarabine 1 busulfan 6 antithy-
mocyte globulin. Two of the 37 patients were
transplanted from a donor with a single antigen mis-
match. Stem cell sources were bone marrow (n 5 8)
or peripheral blood (n 5 29). Median time from diag-
nosis to SCT was 8 months. Multivariate analysis of
the impact of patient and treatment variables on sur-
vival outcomes was not performed.
Related Allogeneic SCT
Kro¨ger et al. [21] compared the outcomes of 38
adult (mean age, 43.5 years) patients with MDS or
sAML who underwent syngeneic SCT to 1444 pa-
tients (mean age, 37.7 years) who underwent HLA-
identical sibling allogeneic SCT and were reported
to the EBMT registry. At the time of SCT, 24% and
35% of the twin and sibling groups, respectively,
were in CR. An unspecified TBI-containing condi-
tioning regimen was used in 36% of the twin group
and 48% of the sibling group; the remaining patients
received an unspecified non-TBI-based regimen. In
the twin and sibling groups, stem cell sources were
Biol Blood Marrow Transplant 15:137-172, 2009 153Role of Cytoxic Therapy with HSCT in the Therapy of MDSbone marrow (57% and 70%) or peripheral blood
(43% and 30 %), respectively. Median time from diag-
nosis to SCT was 7.8 and 9.5 months in the twin and
sibling groups, respectively. In multivariate analysis,
disease status, stem cell source, and age significantly
influenced OS, and stem cell source influenced DFS.
Valcarcel et al. [22] presented the outcomes of 93
adult patients (21-70 years) with high-risk MDS (n 5
34, 37%) or AML (n 5 59) who underwent an HLA-
identical sibling donor peripheral blood allogeneic
SCT (one patient underwent BMT) following reduced
intensity conditioning with busulfan 1 fludarabine.
Outcomes were stratified by disease. Sixty-seven pa-
tients (72%) received induction chemotherapy, of
whom 46 (49%) achieved CR1, and 11 patients
(12%) had also undergone a prior autologous SCT.
Median time from diagnosis to SCT was not reported.
Inmultivariate analysis, incidence of chronic graft-ver-
sus-host disease (cGVHD) significantly influenced OS
and DFS, and disease status influenced DFS.
Sierra et al. [23] reported the results of 452 adult
(median age, 38 years) patients with MDS who re-
ceived HLA-identical sibling allogeneic SCT and
were registered with the IBMTR. Of the 133 (29%)
patients for whom information was available, 73
(55%) received induction chemotherapy. Condition-
ing regimens included TBI in 44% of patients. The in-
terval between diagnosis and SCT was\1 year in 341
(75%) patients. In multivariate analysis, OS and DFS
were influenced by age, percentage of marrow blasts,
and platelet counts before allogeneic SCT.
Sutton et al. [24] presented the outcomes of 71
adult (median age, 37 years) patients with de novo
MDS who underwent HLA-identical sibling BMT
and were registered with the French Bone Marrow
Transplant Registry (FBMTR). Seventeen patients re-
ceived induction chemotherapy consisting of cytara-
bine 1 anthracycline, and CR was achieved in 6 cases.
Conditioning regimens varied by center, but the ma-
jority of patients received either TBI1 cyclophospha-
mide (n 5 26) or busulfan 1 cyclophosphamide (n 5
17). The remaining 28 patients received other high-
dose chemotherapy agents, plus TBI in 25 cases. Me-
dian time between diagnosis and BMT was 201 days.
In multivariate analysis, OS was influenced by age,
sex, previous induction chemotherapy, and percentage
of marrow blasts before BMT. Event-free survival
(EFS) was influenced by the same variables except sex.
Wallen et al. [25] reported the results of 52 older
adult (60-68 years) patients with MDS (n 5 35, 67%),
chronic myeloid leukemia (CML, n 5 8), AML (n 5
6), or other diagnoses (n 5 3) who underwent HLA-
matched or mismatched sibling allogeneic SCT. Con-
ditioning regimens consisted of cyclophosphamide 1
busulfan (67%), cyclophosphamide 1 TBI (21%),
busulfan 1 fludarabine (10%), or cyclophosphamide
alone (2%). Stem cell sources were bone marrow(n 5 26) or peripheral blood (n 5 21). The median
interval from diagnosis to SCT was not stated. Multi-
variate analysis of the impact of patient and treatment
variables on survival outcomes was not performed.
O’Donnell et al. [26] presented the outcomes of 38
patients (median age, 35 years) with severe MDS
(79%) or sMDS/AML who underwent HLA-identical
sibling allogeneic BMT following a conditioning reg-
imen of busulfan 1 cyclophosphamide. The median
interval from diagnosis to BMT was 5 months. Multi-
variate analysis of the impact of patient and treatment
variables on survival was not performed.
Unrelated Allogeneic SCT
Lim et al. [27] reported the results of a prospective
study of 75 adults (19-68 years) who received a RIC
regimen prior to allogeneic SCT using HLA-matched
or mismatched unrelated donors for the treatment of
MDS (68%), AML with tri-lineage dysplasia, or
myelodysplastic/myeloproliferative disorders (MDS-
MPDs). A total of 55 (73%) patients received induction
chemotherapy prior to allogeneic SCT. Three patients
had received a prior autologous SCT. Stem cell sources
were bone marrow (n 5 38) or peripheral blood (n 5
47). Fifty-two donors were HLA- matched, 20 had
a 1 HLA locus mismatch, and 3 were mismatched at
2 HLA loci. Reduced intensity conditioning consisted
of fludarabine 1 busulfan 1 alemtuzumab. In multi-
variate analysis, presence of HLA mismatch signifi-
cantly influenced OS and DFS, and disease status at
allogeneic SCT and the Hematopoietic Cell Trans-
plantation Comorbidity Index (HCT-CI) score signif-
icantly influenced OS.
Castro-Malaspina et al. [28] reported the results of
510 adult (median age, 38 years) patients with MDS
who underwent a matched or mismatched unrelated
BMT facilitated by the National Marrow Donor Pro-
gram (NMDP). Conditioning regimens consisted of
cyclophosphamide 1 fractionated or single dose TBI
6 other (62%), busulfan1 cyclophosphamide6 other
(25%), busulfan 1 cyclophosphamide 1 f-TBI (4%),
or other (9%). Median time from diagnosis to alloge-
neic SCT was 9 months. The majority of patients re-
ceived marrow from an unrelated donor who was
a known HLA-match at the antigen or allele level (n
5 376, 74%), 110 (22%) received marrow from
a known HLA-mismatch at the antigen or allele level,
and 24 (5%) received marrow with a potential antigen-
match at HLA-A, -B, -DRB1 (antigen level for one, al-
lele level for the other in the donor-recipient pair). In
multivariate analysis, DFS and OS were significantly
influenced by FAB, cell dose, recipient cytomegalovi-
rus (CMV) serology, time from diagnosis to SCT,
and year of SCT. OS was also significantly influenced
by donor match.
Arnold et al. [29] presented the outcomes of 118
patients (61% $18 years) with MDS (81%) or sAML
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nors and were reported to the EBMT registry. Sixty-
nine patients received conditioning consisting of
unspecified chemotherapy1TBI, 30 received chemo-
therapy only, and the conditioning regimen was un-
known for 19 patients. Donors were HLA-matched
(n 5 105) or 1-2 HLA locus mismatched (n 5 13).
Multivariate analysis of the impact of patient and treat-
ment variables on survival outcomes was not per-
formed.
Anderson et al. [30] reported the outcomes of 52
patients (median age, 32.6 years) with MDS (75%) or
sAMLwho received unrelated donor SCT.Condition-
ing regimens consisted of cyclophosphamide 1 TBI
(n 5 33) or busulfan 1 cyclophosphamide (n 5 19).
Donors were HLA matched (n 5 34), 1 HLA locus
mismatched (n 5 17), or mismatched at 2 HLA loci
(n 5 1). Multivariate analysis of the impact of patient
and treatment variables on survival outcomes was not
performed.
Kernan et al. [31] reported the outcomes of 462 pa-
tients with malignant or nonmalignant diseases who
received an unrelated donor allogeneic SCT facilitated
by the NMDP. Of these, 32 (7%) were patients with
MDS (median age, 24.3 years). Pretransplant factors
specific to the MDS patients were not reported. Me-
dian interval from diagnosis to SCT for MDS patients
was 0.9 year. No multivariate analysis specific to MDS
outcome was reported.
Related or Unrelated Allogeneic
SCT (or unspecified donor relation)
Yakoub-Agha et al. [32] presented the outcomes
for 70 adult (16-55 years) patients with therapy-related
MDS (n5 31, 44%) or therapy-related AML who un-
derwent HLA-matched or mismatched related (n 5
62) or unrelated (n 5 8) allogeneic SCT using stem
cells from bone marrow (n 5 66), peripheral blood
(n5 3), or unrelated cord blood (n5 1) and were reg-
istered with the FBMTR. Thirty-three patients re-
ceived induction chemotherapy, 24 (34%) of whom
were in CR at the time of SCT. Conditioning regi-
mens consisted of cyclophosphamide 1 TBI (n 5
11), busulfan 1 cyclophosphamide (n 5 26), cyclo-
phosphamide 1 melphalan (n 5 4), other high-dose
chemotherapy6TBI (n5 25), or other non-TBI reg-
imens (n 5 4). Median time from diagnosis to trans-
plantation was 5.7 months. In multivariate analysis,
age, sex, disease status at SCT, presence of CMV,
and conditioning regimen significantly influenced
OS and EFS.
Kerbauy et al. [33,34] presented the outcomes of
43 adult (median age, 48 years) patients with chronic
myelomonocytic leukemia (CMML) (38 de novo, 5 sec-
ondary) who underwent HLA-identical or mis-
matched related (n 5 21) or HLA-matched or
mismatched unrelated (n 5 22) allogeneic SCT fol-lowing conditioning with various busulfan- or TBI-
based regimens. Eleven (26%) patients had received
pretransplant induction chemotherapy. Stem cell
sources were bone marrow (n 5 23) or peripheral
blood (n 5 20). The median interval from diagnosis
to SCT was 8 months. In multivariate analysis,
HCT-CI score significantly influenced OS.
Anderson et al. [35,36] presented the outcomes of
93 adult (median age, 30 years) patients with MDS
who received a conditioning regimen of cyclophospha-
mide1TBI (n5 88) or busulfan1 cyclophosphamide
(n5 5) followed by HLA-matched related (n5 87) or
unrelated (n5 6) donor allogeneic BMT. The median
interval from diagnosis to BMT was 10 months. Mul-
tivariate analysis of the impact of patient and treatment
variables on survival outcomes was not performed.
Nevill et al. [37] presented the results of 60 adult
(15-55 years) patients with MDS (80%) or sAML
who underwent HLA-matched or mismatched related
(n5 38) or unrelated (n5 22) donor allogeneic BMT.
Nineteen (32%) patients received induction chemo-
therapy prior to BMT, 9 of whom attainedCR. Condi-
tioning consisted of cyclophosphamide1 fractionated
TBI for unrelated donor BMT and busulfan 1 cyclo-
phosphamide for related donor BMT. Median time
from diagnosis to BMT was 2.9 months. In multivari-
ate analysis, cytogenetic risk group significantly influ-
enced EFS.
Appelbaum et al. [38] reported the outcomes for 59
adult (median age, 29 years) patients with MDS (83%)
or other hematologic disorders, who underwent HLA-
matched or mismatched related (n 5 57) or unrelated
(n 5 2) allogeneic BMT following conditioning with
cyclophosphamide 1 TBI or busulfan 1 cyclophos-
phamide regimens. Median time from diagnosis to
BMT was 12 months. In multivariate analysis, OS
andDFSwere significantly influenced by age and cyto-
genetics.
Deeg et al. [39] presented the outcomes for 50
adult (55-66 years) patients with MDS who received
conditioning regimens consisting of busulfan1 cyclo-
phosphamide (n 5 27), cyclophosphamide 1 fraction-
ated TBI (n 5 15), cyclophosphamide 1 fractionated
TBI with lung and liver shielding (n5 4), or busulfan1
fractionated TBI (n 5 4), followed by HLA-matched
or mismatched related (n 5 44) or matched unre-
lated (n 5 6) donor allogeneic BMT. Forty-two pa-
tients had de novo MDS, and 8 patients had therapy-
related MDS. Three (6%) patients received induc-
tion chemotherapy. The median time from diagnosis
to BMT was not reported. Multivariate analysis of
the impact of patient and treatment variables on sur-
vival outcomes was not performed.
Kro¨ger et al. [40] reported the results of 50 adult
(19-61 years) patients with de novoCMMLwho under-
went anHLA-matched ormismatched related (n5 44)
or matched unrelated (n 5 6) donor allogeneic SCT.
Biol Blood Marrow Transplant 15:137-172, 2009 155Role of Cytoxic Therapy with HSCT in the Therapy of MDSTwenty-six patients received a TBI-containing condi-
tioning regimen, and 24 patients received a chemother-
apy-based regimen. Stem cell sources were bone
marrow (n 5 40), peripheral blood (n 5 9), or both
(n 5 1). Median time from diagnosis to SCT was 9
months. Multivariate analysis of the impact of patient
and treatment variables on survival outcomes was not
performed.
Bornha¨user et al. [41] presented the outcomes of
42 adult (12-65 years) patients with MDS (62%),
sAML (29%), orCML (9%)who received amyeloabla-
tive conditioning regimen of fludarabine (120 mg/m2)
1 busulfan (16 mg/kg) followed by an HLA-matched
related (n 5 16) or HLA-matched or mismatched un-
related (n 5 26) donor allogeneic peripheral blood
SCT (PBSCT). Five MDS patients and 10 sAML pa-
tients received induction chemotherapy. Median time
from diagnosis to PBSCT was 9 months. Multivariate
analysis of the impact of patient and treatment vari-
ables on survival outcomes was not performed.
Mattijssen et al. [42] presented the results of 35
adult (23-60 years) patients with MDS (91%) or
sAML who received HLA-matched or mismatched
sibling or other related donor (n5 33) or matched un-
related donor (n5 2) allogeneic BMT after condition-
ing with cyclophosphamide 1 TBI 6 idarubicin (n 5
31) or other unspecified schedules (n 5 4). Nineteen
(54%) patients received induction chemotherapy, 15
of whom achieved CR. Stem cell source was T cell-de-
pleted bone marrow for all patients. The median inter-
val from diagnosis to BMTwas 9 months. Multivariate
analysis of the impact of patient and treatment vari-
ables on survival outcomes was not performed.
Autologous versus Allogeneic SCT
Oosterveld et al. [43] reported the results of a retro-
spective analysis of a prospective study by De Witte
et al. [44] comparing autologous SCT (no donor
group) versus allogeneic SCT (donor group) in 184
adult (16-60 years) patients with MDS (75%) or
sAML registered with the EORTC. In this analysis,
only patients alive 8 weeks from the start of treatment
were included (n 5 159). HLA typing was performed
for 128 of the 159 patients (81%), of whom 52 had
an HLA-identical sibling (donor group) and 65 did
not (no donor group). Eleven patients with no siblings
were typed, but excluded. Induction treatment con-
sisted of idarubicin1 cytarabine1 etoposide. Patients
achieving CR received a consolidation course of cytar-
abine 1 mitoxantrone, followed by a transplantation
regimen consisting of either cyclophosphamide 1
f-TBI or busulfan 1 cyclophosphamide, then either
allogeneic SCT (donor group, n 5 28) or autologous
SCT (no donor group, n 5 27). Analyses were based
on intention to treat. Reasons for not receiving the
assigned SCT included death, treatment failure,toxicity, protocol violation, patient refusal, or receipt
of a nonsibling allogeneic SCT. In multivariate
analysis, cytogenetic risk group significantly influ-
enced OS.
De Witte et al. [45,46] reported the outcomes of
1378 adult (81% $20 years) patients who underwent
transplantation for treatment of MDS (.60%) or
sAML and were reported to the EBMT. Of the total,
1347 patients received an allogeneic SCT from an
HLA-identical sibling donor (n 5 885), HLA-non-
identical family donor (n5 91), or an unrelated donor
(n 5 198), and 173 patients underwent an autologous
SCT. Conditioning regimens were not reported. Of
the 885 patients who received an allogeneic SCT
from an HLA-identical sibling, 665 (75%) had an in-
terval from diagnosis to SCT of\12 months (not re-
ported for the other groups). In multivariate analysis,
age had a significant influence on survival for all but
the nonidentical related allogeneic SCT group, and
stage of disease had a significant impact on survival
in both related allogeneic SCT groups.
TRANSPLANTATION TECHNIQUES
This section describes studies that examine the im-
pact of stem cell source and conditioning regimen on
patient outcomes in the treatment of MDS. Table 6
presents a summary of the patient outcomes from these
studies.
BMT versus PBSCT
Allogeneic BMT versus PBSCT
Couban et al. [47] presented the results of 227
adult (19-64 years) patients with MDS (n 5 36),
CML (n5 109), or AML (n5 82) who were randomly
assigned to receive either bone marrow or peripheral
blood stem cells for anHLA-matched sibling donor al-
logeneic SCT. Of the 36 MDS patients, 20 received
bone marrow and 16 received peripheral blood stem
cells. The conditioning regimen consisted of busulfan
1 cyclophosphamide. Median time from diagnosis to
SCT was not reported. Multivariate analysis of the im-
pact of patient and treatment variables on survival out-
comes was not performed. Figure 3 presents OS by
stem cell source.
Guardiola et al. [48] reported the results of 234
adult (75%.35 years) patients with MDS who under-
went HLA-matched sibling allogeneic SCT, compar-
ing the use of bone marrow (n 5 132) versus
peripheral blood (n 5 102) as the stem cell source.
Of the total, 131 patients received high-dose induction
chemotherapy, 70 of whom achieved CR. The condi-
tioning regimen was not reported. For 53% of pa-
tients, time from diagnosis to SCT was #6 months.
In multivariate analysis, stem cell source influenced
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uthor/ Reference #
Quality and Strength of
Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated) Median Follow-up Study Groups (n)
T VERSUS PBSCT
logeneic BMT versus PBSCT
[47] 1+ 1996-2000
Randomized
Multicenter (8)
Total n 5 227
MDS n 5 36
Conditioning
Bu + Cy
MDS 16%
CML 48%
AML 36%
32.8 months (MDS only)
BMT (20)
Age range: 19-64
BMT
Median age, 44 years
PBSCT
Median age, 45 years
HLA-matched sibling
allo-SCT
PBSCT (16)
(ITT analysis)
[48] 2+ 1995-1999
EBMT
Multicenter (72)
n 5 234
High-dose IC
56% received
53% achieved CR
RA 29%
RAEB 37%
RAEBt 32%
Unclassified 2%
1 year
BMT
Age range: 4-59
Median age, 41 years
68% >35 years
Conditioning regimen
not stated
BMT (132)
PBSCT
Age range: 12-60
Median age, 47 years
84% >35 years
HLA-matched sibling
allo-SCT
PBSCT (102)
[49] 2+ 1985-2001
GETH Registry
Multicenter
n581
Conditioning
Bu+Cy
Cy+TBI
Other
Low-risk
RA 16%
RARS 4%
8.5 months
Age range: 8-52
Median age, 39 years
54% $40 years
HLA-identical sibling
allo-SCT
High-risk
RAEB 38%
RAEBt 26%
Overall
BM (45)
PBSC (36)
CMML 7%
Other 9% Low-risk MDS
BM (6)
PBSC (10)
High-risk MDS
BM (33)
PBSC (19)
Not stated (4–year %DFS) Not stated
28%
21%
(P5.66)
(3-year %TRM) (3-year %PFS) (3-year %OS)
22% (CI 17%-28%) 33% (CI 27%-40%) 41% (CI 35%-47%)
32% (CI 28%-36%) 41% (CI 37%-45%) 45% (CI 41%-49%)
(P 5 .04) (P510) (P5.70)
(3-year %TRM) (3-year %PFS) (3-year %OS)
39% 27% 28%
32% 44% 48%
(P 5 .94) (P5.10) (P5.56)
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[50] 2+ Post 1992
EBMT
Multicenter
n 5 336
Conditioning
not stated
de novo MDS 19%
t MDS 17%
sAML 27%
Unknown etiology 37%
Not stated
Auto-SCT
BM (104)
PBSC (232)
Age range 0-73
Median age, 49 years
87% >29 years
73% MDS
CONDITIONING REGIMEN COMPARISONS
Reduced Intensity Conditioning Versus High-Dose Regimen
[51] 2++ 1997-2001
EBMT
Multicenter (128)
n 5 836
Conditioning
RIC
Bu + Flu
Flu + Mel
Flu + Low-dose TBI
Flu + Other
RIC
RA/RARS 9%
RAEB 27%
RAEBt 13%
sAML 35%
Unclassified 16%RIC‡
Age range: 27-72
Median age, 56 years
High-dose
TBI + Cy/Other
Bu + Cy
Bu + Cy/Other
Alemtuzumab
None or not specified
High-dose
RA/RARS 11.5%
RAEB 20%
RAEBt 21.5%
sAML 32%
Unclassified 15%
RIC
38 months
RIC (215)
High dose
Age range: 18-67
Median age, 45 years HLA-identical sibling
allo-SCT
High dose
50 months
High dose (621)
67% MDS
[52] 2+ 1998-2003
2 centers
n 5 150
Induction Chemo
RIC
22% received,
83% achieved CR
RIC
RA/RARS 23.5%
RAEB 23.5%
RAEBt/tAML 53%
Age range: 40-72
High dose
63% received,
64% achieved CR
High dose
RA/RARS 38%
RAEB 31%
RAEBt/tAML 31%
RIC
614 days
RIC
(38)
RIC
Median age, 62 years
Conditioning
RIC
2 cGy TBI ± Flu
High dose
789 days
High dose (112)
High dose
Median age, 53 years
High dose
Oral t-Bu + Cy
HLA-matched related
or unrelated allo-
SCT
nterval)
TRM
(Interval)
% DFS/RFS/EFS/PFS
(Significance)
(Interval)
% OS
(Significance)
%TRM) (2-year %DFS) (2-year OS)
1% 39% 48%
0% 44% 44%
tated) (P not stated) (P not stated)
%TRM) Not Stated (2-year %OS)
1% 53.8%
(CI 26.8%-80.8%)
23.5% 45%
(CI 23.2%-66.8%)
tated) (P not stated)
%TRM) (3-year %RFS) (3-year %OS)
12% 37%±11% 39%±12%
9% 59%±11% 66%±11%
) (P5.059) (P5.02)
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Author/ Reference #
Quality and Strength of
Evidence* Patient Population† Protocols
Diagnosis or Subtype
(at Dx Unless
Otherwise Stated) Median Follow-up Study Groups (n)
(I
%
[53] 2+ 1993-2000
Multicenter
(4)n 5 52
Induction Chemo
RIC
48% received,
63% achieved CR
High dose
55% received,
50% achieved CR
RA 34.5%
RAEB 27%
RAEBt 5.5%
t-MDS/AML 10%
sAML 23%
(2-year
67% MDS Conditioning
RIC
Bu + Flu + Campath
RIC
10 months
RIC (23) 3
High dose
Bu + Cy + TBI +
Campath
High dose
42 months
High dose (29) 5
HLA-matched or
mismatched related
or unrelated allo-
SCT
(P not s
[54] 2+ 1998-2002
Multicenter (55)
Total n 5 207
MDS n550 (24%)
Conditioning
RIC
Cladribine-based
Flu-based
2 Gy TBI-based
MDS only (no FAB
subtypes stated)
(1-year
3Age range: 50-59 High dose
12 Gy TBI-based
Bu + Cy
Bu + Cy + TBI
RIC
20.3 months
RIC (16)
RIC
Median age, 57 years
HLA-identical sibling
allo-SCT
High dose
31.6 months
High dose (34)
(P not s
High dose
median age, 52 years
[55] 2+ 1997-2004
Single center
n 5 43
Conditioning
RIC
Flu + Cy or Mel or
i.v. Bu
18 months (3-year
Age range: 12-73
Median age, 49 years HLA-identical sibling,
unmanipulated allo-
PBSCT
RIC
RAEB 50%
RAEBt 15%
AML 35%
RIC (20) 27% ±
70% MDS High dose
Cy + f-TBI
Cy + Flu + f-TBI
High dose
RA/RARS 31%
RAEB 17%
RAEBt 26%
AML 26%
High dose (23) 17% ±
HLA-identical sibling,
T cell-depleted allo-
PBSCT
(P 5 .22
ar %TRM) (3-year %RFS) Not stated
50 24
37 19
t signif) (P not signif)
ar %TRM) (3-year %DFS) Not stated
68% 23%
36% 30%
(P 5 .12) (P5.60)
ar %TRM) (3-year DFS) Not stated
37 63
37 60
(P 5 .90) (P5.90)
complete remission; DX, diagnosis; MDS, myelodysplastic
mia with excess blasts in transformation; CMML, chronic
hronic myelologenous leukemia; EBMT, European Group
, treatment-related mortality; DFS, disease-free survival;
n chemotherapy; Flu, Fludarabine; Cy, Cyclophosphamide;
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
5
:1
3
7
-1
7
2
,
2
0
0
9
1
5
9
R
o
le
o
f
C
yto
x
ic
T
h
e
ra
p
y
w
ith
H
S
C
T
in
th
e
T
h
e
ra
p
y
o
f
M
D
SComparison of $2 High-Dose Regimens
[56] 2+ 1992-2002
Single center
n 5 128
Induction Chemo
35 patients received
(25 achieved CR)
Bu + TBI
RAEB 44%
RAEBt 34%
tAML 22%
Not stated (3-ye
Bu + TBI
Age range: 1-56
Median age, 45 years
Conditioning
Oral Bu+TBI (200 cGy)
or
Oral t-Bu + Cy
t-Bu + Cy
RAEB 57%
RAEBt 15%
tAML 28%
Bu + TBI (50)
t-Bu + Cy
Age range: 3-66
Median age, 52 years
HLA-matched related
or unrelated allo-
SCT
t-Bu + Cy (78)
74% MDS (P no
[57] 2+ 1990-1993
Single center
Total n 5 75
Conditioning
Cy + TBI
Oral Bu + Cy +
2 Gy TBI
Cy + TBI
RAEB 68%
RAEBt 32%
Not stated (3-ye
Current
Bu + Cy + TBI, n 5 31
Age range: 16-54
Median age, 41 years
HLA-matched or
mismatched related
or unrelated allo-
SCT
Bu + Cy + TBI
RAEB 48%
RAEBt 26%
CMML 26%
Cy + TBI (44)
Historic
Cy + TBI, n 5 44
Age range: 1-55
Median age, 36 years
Bu + Cy + TBI (31)
[58] 2+ 1990-1993
Single center
Total n 5 68
Conditioning
Oral Bu + Cy
Cy + TBI
MDS
RA 100%
Not stated (3-ye
Age range: 5-53
71% >20 years HLA-matched or
mismatched related
or unrelated allo-
SCT
Bu + Cy (28)
Current
Bu + Cy, n 5 30,
Analyzed n 5 28
Median age, 29 years
Cy + TBI (38)
Historic
Cy + TBI, n 5 38
Median age, 28 years
*Quality and strength of evidence definitions are listed in Table 1.
†Auto indicates autologous; Chemo, chemotherapy; SCT, stem cell transplantation; BMT, bone marrow transplantation; PBSCT, peripheral blood SCT; CR,
syndromes; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEBt, refractory ane
myelomonocytic leukemia; MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; sAML, secondary AML; tAML, therapy-related AML; CML, c
for Blood and Marrow Transplantation; GETH, Grupo Espan˜ol de Trasplante Hematopoyetico; HLA, human leukocyte antigen; ITT, intention to treat; TRM
EFS, event-free survival; RFS, relapse-free survival; PFS, progression-free survival; OS, overall survival; CI, 95% confidence interval; HD, high dose; IC, inductio
Bu, Busulfan; t-Bu, targeted Busulfan; Mel, Melphalan; TBI, total-body irradiation; f-TBI, fractionated TBI; RIC, reduced-intensity conditioning.
‡For simplicity, reduced-intensity and nonmyeloablative conditioning regimens are listed as RIC; myeloablative regimens are listed as high dose.
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(RA) or high-risk cytogenetics.
del Can˜izo et al. [49] presented the outcomes of 81
adult (median age, 35 years) patients with de novoMDS
who underwent an HLA-identical sibling allogeneic
SCT, comparing low risk (RA and RARS, n5 16) ver-
sus high-risk (RAEB and RAEBt, n 5 52) MDS by
stem cell source (bone marrow, n 5 45 versus periph-
eral blood, n 5 36). Conditioning regimens consisted
of busulfan 1 cyclophosphamide (n5 42), cyclophos-
phamide 1 TBI (n 5 32), or other (n 5 7). Median
times from diagnosis to SCT were 9.5 and 6 months
for the bone marrow and peripheral blood stem cell
groups, respectively. Inmultivariate analysis no patient
or treatment variables were significantly associated
with OS. Figure 4 presents EFS by stem cell source
for the RAEB/RAEBt (high-risk) group.
Figure 3. OS by treatment arm for MDS. (Reprinted with permission,
Couban et al., 2002.)
Figure 4. EFS in the RAEB/RAEB-t group according to the cell source.
(Reprinted with permission, del Can˜izo et al., 2003.)Autologous BMT versus PBSCT
De Witte et al. [50] reported the outcomes of 336
adults (87% were .29 years) with MDS (73%) or
sAML who were transplanted after 1992 with autolo-
gous SCT using either bone marrow (n 5 104) or pe-
ripheral blood stem cells (n5 232) and reported to the
EBMT Registry. MDS patients were classified as hav-
ing primaryMDS (19%), therapy-relatedMDS (17%),
or MDS of unknown cause (37%). Patients receiving
peripheral blood stem cells tended to be older than pa-
tients receiving bone marrow (26% versus 8%, respec-
tively, were.60 years). The conditioning regimen was
not stated. The intervals from diagnosis to SCT were
#5 months (32%), 5-8 months (44%), and.8 months
(24%). In multivariate analysis, disease status and year
of transplant significantly influenced DFS.
Conditioning Regimen Comparisons
Comparison of RIC Versus High-Dose Regimens
Martino et al. [51] presented the results of 836
adult (18-72 years) patients with MDS (67%) or
sAML who underwent HLA-identical sibling alloge-
neic SCT, comparing the outcomes of patients who re-
ceived reduced intensity (n 5 215) versus high-dose
(n5621) conditioning regimens. Stem cell sources
for the reduced intensity and high-dose conditioning
groups were bone marrow (12.6% and 49.1%) or pe-
ripheral blood (87.4% and 50.9%), respectively. For
the majority of patients, time from diagnosis to SCT
was\6 months (reduced intensity, 73.5%; high dose,
77.4%), and 25% of reduced intensity and 11% of
high-dose conditioning patients underwent a prior
autologous SCT. In multivariate analysis, disease
type, disease status, and age significantly influenced
OS and progression-free survival (PFS).
Scott et al. [52] reported the results of 150 adult (40-
72 years) patients withMDS (63%) or RAEBt/therapy-
related AMLwho received a high-dose (oral busulfan1
cyclophosphamide, n5 112) or reduced intensity (2 Gy
TBI 6 fludarabine, n 5 38) conditioning regimen fol-
lowed byHLA-matched related or unrelated allogeneic
SCT. Induction chemotherapy consistingof cytarabine-
containing regimens was used in 22% and 63% of pa-
tients in the high-dose and reduced intensity condition-
ing groups, respectively. Of those, 16 (64%) and 20
(83%), respectively, achieved a CR pre-SCT. Stem cell
sourceswerebonemarrow (81%and95%)orperipheral
blood (19% and 5%) for the high-dose and reduced in-
tensity conditioning groups, respectively. Median dis-
ease duration was 7 and 9 months for the high-dose
and reduced intensity conditioning groups, respectively.
In multivariate analysis, no patient or treatment vari-
ables were significantly associated with OS or PFS.
Parker et al. [53] compared patient outcomes by
conditioning regimen for 52 adult (18-63 years)
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MDS/AML who underwent matched or mismatched
related or unrelated donor allogeneic SCT following
high dose (busulfan 1 cyclophosphamide 6 TBI and
Campath-1G; n 5 29) or reduced intensity (busulfan
1 fludarabine 1 Campath-1G; n 5 23) conditioning
regimens. Twenty-seven patients (52%) received prior
induction chemotherapy, and 13 of these were in CR at
time of SCT. The median time from diagnosis to SCT
was 10 months for the high-dose conditioning and 16
months for the reduced intensity conditioning groups.
Stem cell sources were bone marrow (72% and 78%)
or peripheral blood (28% and 22%) for the high-
dose and reduced intensity conditioning groups,
respectively. Multivariate analysis of the impact of
patient and treatment variables on survival outcomes
was not performed.
Kojima et al. [54] presented the results of 207 adult
(50-59 years) patients with MDS (n5 50, 24%), AML
(n5 89), ALL (n5 35), or CML (n5 33), comparing
the outcomes of reduced intensity (purine analog-
based or 2GyTBI-based) versus high-dose (TBI-based
or busulfan 1 cyclophosphamide-based) conditioning
regimens followed by HLA-identical sibling donor
allogeneic SCT. Patient outcomes were stratified by
disease (MDS; reduced intensity, n 5 16; high dose,
n5 34). Patient characteristics and pretransplant factors
specific to the MDS patients were not reported. No
multivariate analysis specific to MDS outcome was re-
ported. Figure 5 presents OS by conditioning regimen.
Solomon et al. [55] reported the outcomes of 43
adult (12-73 years) patients with MDS who received
a reduced intensity (fludarabine 1 cyclophosphamide,
melphalan, or intravenous busulfan, n 5 20) or high-
dose (fractionated TBI1 cyclophosphamide6 fludar-
abine, n 5 23) conditioning regimen followed by
HLA-identical sibling donor allogeneic SCT. Patients
receiving reduced intensity conditioning were older
and had more aggressive disease than patients in the
Figure 5. Overall survival (OS) following CSTand RIST in all patients.
There was no significant difference in OS between CST and RIST (P 5
.25). (Reprinted with permission, Kojima et al. 2005.)high-dose conditioning group. The high-dose group
received a T cell-depleted peripheral blood SCT,
and the reduced intensity group received a T cell-re-
plete peripheral blood SCT. Median time from diag-
nosis to SCT was not reported. In multivariate
analysis, MDS etiology (de novo versus secondary) sig-
nificantly influenced DFS.
Comparison of $2 High-Dose Regimens
Scott et al. [56] presented the outcomes of 128 pa-
tients with advanced MDS (74%) or therapy-related
AML who underwent HLA-matched related or unre-
lated allogeneic SCT after conditioning with either
oral busulfan 1 TBI (n 5 50, median age 45 years)
or targeted oral busulfan 1 cyclophosphamide (n 5
78, median age 52 years). Patients who received busul-
fan1TBI were more likely to have an unrelated donor
and to receive bone marrow, and patients conditioned
with busulfan 1 cyclophosphamide were more likely
to have a related donor and to receive an allogeneic
PBSCT. Median time from diagnosis was 6 months
for both conditioning groups. In multivariate analysis,
conditioning regimen did not significantly influence
OS, RFS, or treatment-related mortality (TRM).
Anderson et al. [57] compared the outcomes of 31
adult (median age, 41 years) patients with advanced
MDS who were conditioned with oral busulfan 1 cy-
clophosphamide 1 TBI to the outcomes of 44 histor-
ical controls (median age, 36 years) conditioned with
cyclophosphamide 1 TBI prior to HLA-matched or
mismatched related or unrelated donor allogeneic
BMT. Median times from diagnosis to SCT were 5
and 8.5 months for the treatment and historic control
groups, respectively. In multivariate analysis, karyo-
type and WBC count significantly influenced DFS,
and karyotype influenced OS.
Anderson et al. [58] compared the results of 30 pa-
tients (median age, 29 years) with RA conditioned with
oral busulfan 1 cyclophosphamide to 38 historic con-
trols (median age, 28 years) with refractory anemia
conditioned with cyclophosphamide 1 TBI prior to
matched or mismatched related or unrelated donor al-
logeneic BMT. Median times from diagnosis to BMT
were 10 and 11 months for the treatment and historic
control groups, respectively. In multivariate analysis,
age (decade), time from diagnosis to BMT, neutrophil
count at BMT, and hematocrit significantly influenced
OS.
MDS PROGNOSTIC SCORING SYSTEMS AND
FACTORS
This section provides a summary of MDS classifi-
cation and scoring systems. The data in this section are
provided for the reader’s information and were not
used to make treatment recommendations.
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The FAB classification system has been used since
1982 to categorize MDS patients [59]. FAB system
limitations [60] led to a revisedMDS classification sys-
tem in 1999 by the World Health Organization
(WHO) [61]. The following articles compared the
classification of MDS by FAB versus WHO systems.
Germing et al. [62] conducted a retrospective anal-
ysis of 1600 adult (16-96 years) patients with MDS, di-
agnosed between 1970 and 1999 at a single center, to
compare the FAB and WHO classification systems as
summarized in Table 7. According to the FAB sub-
types, RARS had the best prognosis (median survival,
50 months), followed by RA (37 months), CMML
(19 months), RAEB (12 months), and RAEB-t (5
months). Under theWHO system, del (5q) and a med-
ullary blast count\5% reportedly had the best prog-
nosis, followed by pure refractory anemia (PRA) and
pure sideroblastic anemia (PSA) (both 69 months),
RCMD (33 months), RSCMD (32 months), RAEB I
(18 months), RAEB II (10 months), and del (5q), and
a medullary blast count .5% (7 months). Figures 6
and 7 present OS according to the FAB and WHO
classification systems, respectively.
No¨sslinger et al. [63] compared the FAB andWHO
classifications of 431 adult (31-92 years) patients diag-
nosed with de novo MDS at a single center between
1976 and 1999, as summarized in Table 8. In the FAB
system, median survival for RARS was 73 months, fol-
lowed by RA (66 months), CMML (24 months), RAEB
(15 months), and RAEB-t (9 months). Using the WHO
system, the 150 patients with RAEB-t or CMML were
excluded and survival for the RARS and del (5q) groups
Table 7. Patient Reclassification from FAB to WHO System
(Germing et al. [62])*
FAB Classification WHO Classification
Refractory anemia (RA) (n 5 418) Pure refractory anemia (PRA)
(n 5 107)
Refractory cytopenia w/multilineage
dysplasia (RCMD) (n 5 284)
Del (5q) (n 5 18)
Unclassified MDS (n 5 14)
Refractory anemia with ring
sideroblasts (RARS) (n 5 328)
Pure sideroblastic anemia (PSA)
(n 5 138)
Refractory sideroblastic cytopenia
w/multilineage dysplasia (RSCMD)
(n 5 183)
Del (5q) (n 5 7)
Refractory anemia with excess of
blasts (RAEB) (n 5 344)
RAEB-I (n 5 167)
RAEB-II (n 5 172)
Del (5q) (n 5 3)
Refractory anemia with excess of
blasts in transformation
(RAEB-t) (n 5 273)
RAEB-t Excluded (blast count >20%)
(n 5 217)
RAEB-I (n 5 14)
RAEB-II (n 5 42)
Chronic myelomonocytic leukemia
(CMML) (n 5 237)
CMML Excluded (n 5 116)
RCMD (n 5 22)
RAEB-I (n 5 78)
RAEB-II (n 5 21)
*The numbers in this table are presented as originally reported in the
text of the Germing et al. article.were not analyzed because of the small number of pa-
tients. Median survival for RCMD was 86 months, fol-
lowed by unclassified MDS (67 months), RA (66
months),RAEBI (18months), andRAEBII (12months).
Figure 6. Cumulative survival in MDS patients (n5 1405) classified ac-
cording to the FAB group proposals. (Reprinted with permission, Ger-
ming et al., 2000.)
Figure 7. Cumulative survival in MDS patients (n5 1157) classified ac-
cording to the new WHO proposals. (Reprinted with permission, Ger-
ming et al., 2000.)
Table 8. Patient Reclassification from FAB to WHO System
(No¨sslinger et al. [63])
FAB Classification WHO Classification
Refractory anemia/refractory
anemia with ring sideroblasts
(RA/RARS) (n 5 189)
Refractory anemia (RA) (n 5 43)
Refractory anemia with ring
sideroblasts (RARS) (n 5 4)
Refractory cytopenia w/multilineage
dysplasia (RCMD) (n 5 91)
Del (5q) (n 5 1)
Unclassified MDS (n 5 50)
Refractory anemia with excess of
blasts (RAEB) (n 5 92)
RAEB-I (n 5 50)
RAEB-II (n 5 42)
Refractory anemia with excess of
blasts in transformation (RAEB-t)
(n 5 51)
RAEB-t Excluded (blast count of
20% to 30%) (n 5 51)
Chronic myelomonocytic leukemia
(CMML) (n 5 99)
CMML Excluded (n 5 99)
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classification in 467 adult (22-93 years) patients with
de novo MDS at a single institution from 1992 to
2002, as summarized in Table 9. The analysis of prog-
nostic value of the WHO classification found signifi-
cant differences in survival between RA and RCMD
(P \ .001), RAEB I and RAEB II (P \ .001), and
RAEB I and RCMD (P 5 .005).
Table 9. Patient Reclassification from FAB to WHO System
(Malcovati et al. [64])
FAB Classification WHO Classification
Refractory anemia/refractory
anemia with ring sideroblasts
(RA/RARS) (n 5 240)
Refractory anemia (RA) (n 5 76)
Refractory anemia with ring
sideroblasts (RARS) (n 5 34)
Refractory cytopenia w/multilineage
dysplasia (RCMD) (n 5 80)
RCMD w/ring sideroblasts (RCMD-
RS) (n 5 13)
Refractory anemia with excess of
blasts (RAEB) (n 5 131)
RAEB-I (n 5 59)
RAEB-II (n 5 72)
Refractory anemia with excess of
blasts in transformation (RAEB-t)
(n 5 43)
Chronic myelomonocytic leukemia
(CMML) (n 5 53)
CMML excluded (n 5 46)
Del (5q) (n 5 30)
Unclassified MDS (n 5 10)
Secondary AML (sAML) excluded
(n 5 47)marrow blasts, and other factors. These systems ex-
cluded karyotype, which was not commonly available
at the time. Table 10 summarizes the most relevant
and commonly usedMDS scoring systems without kar-
yotype as adapted from Sanz et al. [60].
Prognostic scoring systems with karyotype
Once karyotypes were commonly available, new
prognostic scoring systems were developed, as summa-
rized in Table 11.
MDS Prognostic Factors
Table 12 summarizes patient- and disease-related
prognostic factors and their reported impact on sur-
vival outcomes as determined by multivariate analyses.
Although many of the referenced studies in Table 12
were described in the text and tables of this review,
others were specifically prognostic factor studies not
presented in this evidence-based review since they
did not meet the inclusion criteria [reference numbers
are listed in brackets]. Studies were not included in this
table if they did not conduct a multivariate analysis.
The data in this table are provided for the reader’s in-
formation and were not used to make treatment rec-
ommendations.MDS Prognostic Scoring Systems
Prognostic scoring systems without karyotype
Early MDS scoring systems assigned risk groups
based on number of cytopenias, percentage of bone
NOVEL AGENTS VERSUS SUPPORTIVE CARE
This section describes the impact of various novel
chemotherapy agents versus supportive care in the
treatment of MDS. These studies are restricted to
Table 10. Description of MDS Main Scoring Systems without Karyotype
Points
Prognostic Scoring
System and Variables Included 0 1 2 Risk Group Score
Bournemouth [65,66]
Hemoglobin (g/dL) >10 #10 Low 0 or 1
Neutrophils (109/L) >2.5 and #16 #2.5 and >16 Intermediate 2 or 3
Platelets (109/L) >100 <100 High 4
Marrow blasts (%) <5 >5
Spanish [67]
Marrow blasts (%) <5 5-10 11-30 Low 0 or 1
Platelets (109/L) $100 51-100 #50 Intermediate 2 or 3
Age (years) <5 >60 High 4 or 5
Goasguen [68]
Hemoglobin (g/dL) >10 #10 Low 0
Platelets (109/L) >100 #100 Intermediate 1 or 2
Marrow blasts (%) <5 $5 High 3
Du¨sseldorf [69]
Marrow blasts (%) <5 $5 Low 0
Platelets (109/L) >100 #100 Intermediate 1 or 2
Hemoglobin (g/dL) >9 #9 High 3 or 4
LDH #200 >200
CMML-specific [70]
Hemoglobin (g/dL) $12 <12 Low 0 or 1
Lymphocyte count (109/L) #2.5 >2.5 Intermediate 1 2
Marrow blasts (%) <10 $10 Intermediate 2 3
Immature myeloid cells (%) 0 >0 High 4
Adapted with permission from Sanz et al. ([60], Table 3).
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Points
Prognostic Scoring
System and Variables Included 0 .5 1 1.5 2 3 Risk Group Score
Lille [71]
Marrow blasts (%) <5 5-10 21-30 Low 0
Karyotype Good Poor Intermediate 1 or 2
Platelets (109/L) >75 <75 High 3 or 4
IPSS [9]
Marrow blasts (%) <5 5-10 11-20 11-30 Low
Interm 1
Interm 2
High
0
0.5-1
1.5-2
2.5-3.5
Karyotype Good Poor
Cytopenias 0 or 1
Interm
2 or 3
WPSS [72]
WHO Subtype RA, RARS, 5q-
Good
No
RCMD,
RCMD-RS
Intermediate
Regular
RAEB-1
Poor
RAEB-II Very Low
Low
Intermediate
High
Very High
0
1
2
3 or 4
5 or 6
Karyotype
Transfusion
requirements
SCT—specific [73]
Age <40 $40 Low
Intermediate
High
#2
3
$4
Disease RA,RARS, RCMD RAEB
Stage at SCT Untreated CR >1 or failure
Karyotype Favorable Intermediate Adverse
Ferritin (ng/dL) <2500 $2500
Adapted with permission from Sanz et al. ([60], Table 4).meta-analyses and randomized controlled trials (RCT)
except for the Immunomodulatory Agents section,
which includes phase II studies. The data in this sec-
tion are provided for the reader’s information and
were not used to make treatment recommendations.
Cytokine Therapy
Ross et al. [83] presented the results of a meta-
analysis of 59 studies conducted between 1990 and
2005 to determine the efficacy and safety of erythro-
poiesis-stimulating proteins in the treatment of
MDS. The majority were single-arm studies, and five
(n 5 354) were controlled studies of epoetin versus
control (4 RCT, 1 non-RCT). In the controlled stud-
ies, patients who received epoetin had a significantly
better hemoglobin response (odds ratio, 5.2; 95% con-
fidence interval [CI], 2.5%-10.8%); the overall hemo-
globin response was 27.3%. Three of the RCT studies
in this meta-analysis are described below in more de-
tail.
The Italian Cooperative Study Group [84] re-
ported the outcomes of 87 adult (18-80 years) patients
enrolled in a multicenter, randomized, double-blind,
placebo-controlled study analyzing the effect of re-
combinant human erythropoietin (rHuEpo) on hemo-
globin level and transfusion requirement in low-risk
MDS. In the double-blind phase, patients were ran-
domized to receive 150 U/kg per day of epoetin (n 5
44) or placebo (n 5 43) for 8 weeks. Thirty-eight
and 37 patients in the epoetin and placebo arms, re-
spectively, completed the double-blind phase. Analysis
was on an intention-to-treat basis. A full response was
defined as an increase in hemoglobin by$2 g/dL or notransfusion for at least 2 months; partial response was
defined as an increase in hemoglobin by 1-2 g/dL or
50% decrease in need for transfusion for at least 2
months. For analysis, full and partial responses were
pooled because of the low number of full responses
(epoetin, n 5 5; placebo, n 5 0). There was a signifi-
cantly better response in the epoetin arm (36.8% ver-
sus 10.8%, P 5 .007). Incidence of adverse effects was
not significantly different between the two groups.
Thompson et al. [85] assessed the safety and effi-
cacy of epoetin 1 granulocyte-macrophage colony-
stimulating factor (GM-CSF) for treating anemic,
neutropenic adult (21-95 years) patients with MDS
in a multicenter, randomized, double-blind, placebo-
controlled study. Patients were stratified by their level
of endogenous serum erythropoietin (#500 mU/mL,
n 5 37; .500 mU/mL, n 5 29), then randomized in
a 2:1 ratio to receive either epoetin 1 GM-CSF (n 5
45) or placebo 1 GM-CSF (n 5 21) three times per
week for 12 weeks. Hemoglobin response occurred
in 9% and 5% of patients in the epoetin and placebo
groups, respectively (P not significant). For patients
with.500 mU/mL endogenous erythropoietin levels,
the adjusted mean change in baseline hemoglobin was
greater for the epoetin than for the placebo group
(10.07 g/dL versus 20.96 g/dL, P 5 .048). Transfu-
sions were required for 90% of placebo and 76% of
epoetin groups (P not significant). In the epoetin
group, a significantly lower percentage of patients in
the #500 mU/mL endogenous erythropoietin group
were transfused compared to the .500 mU/mL en-
dogenous erythropoietin group (60% versus 95%, P
5 .0069).
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Analysis Performed in Individual Studies
Prognostic Factor†
References of Studies Reporting Significant
Impact of Prognostic Factor on Survival
References of Studies Reporting No Significant
Impact of Prognostic Factor on Survival
PATIENT CHARACTERISTICS
Age 11, 21, 23, 24, 30, 32, 38, 44, 48, 51, 58, [74], [75], [76],
[77], [78], [79]
10, 12, 15, 17, 22, 27, 28, 43, 50, 55, [80], [81]
Gender 17, 18, 32 12, 23, [74], [81]
DISEASE CHARACTERISTICS AT DIAGNOSIS
MDS etiology (de novo or secondary) 15, 18, 50, 55 17, [77]
WBC count 11, 57 23
FAB subtype 8, 10, 12, 18, 21, 24, 28, 48, 51, 54, [82] 15, 22, 23, 30, 38, 52, 55, [79]
IPSS score 8, [74], [80], [82] 15, 23, 27, 33, 52, [81]
Hemoglobin 11 23
% BM blasts 23, [74], [81] 24, 32, 55
Platelets 11 23, 30, [74]
Cytogenetic risk group/karyotype 11, 12, 17, 38, 30, 37, 38, 43, 57, [74], [75], [76], [77],
[81]
15, 22, 23, 27, 30, 48, 51, 55, [80]
Comorbidities 27, 33, [76]
DISEASE CHARACTERISTICS AT SCT
Time from diagnosis to SCT 8, 10, 17, 18, 28, 58 12, 21, 23, 30, 33, 38, 50, [77], [78], [79], [81]
Prior treatment for MDS (eg, transfusions) 23 30
Induction chemotherapy 12, 24 30, 32, 38, 43, [76]
Disease status at SCT 27, 32, 44, 48, 51, [75], [77] 10, 21, 22, 52
Presence of cytopenia(s) 58 32, [80]
% BM blasts 24 37, [80]
Splenomegaly 23
Recipient-donor CMV status 17, 28, 30, 32 23, [76]
Performance status 54
TREATMENT RELATED FACTORS
Type of SCT (eg, allo, auto) [80] 43
Conditioning regimen 24, 32, 54 12, 17, 21, 23, 28, 30, 33, 51, 55, 56, [76], [77], [78]
Stem cell source 21, 48, [76] 12, 15, 27, 47, 50, [77]
Donor relation 18, [79] 15, 17, 21, 56, [77], [81]
HLA match 27, 28, [75] 30
Year of transplant 28 23, 44, [77], [80], [78]
*Survival 5 any one or more of the following: OS, DFS, RFS, LFS, EFS, PFS.
†Factors were not included if the study did not conduct a multivariate analysis.Casadevall et al. [86] reported the results of 60
adult (43-89 years) patients with MDS and serum
erythropoietin levels\500 mU/mL in a multicenter,
randomized trial comparing recombinant human
(rHu)-Epo 1 rHuG-CSF (arm A, n 5 24) and sup-
portive care (arm B, n5 26). Patients in arm A received
treatment three times per week for 12 weeks, after
which responders were given rHuEpo for another 40
weeks. Patients in arm B received supportive care, in-
cluding transfusion of red blood cells as needed and
iron chelation treatment for 52 weeks. Twenty-one
and 24 patients from arms A and B, respectively, com-
pleted the 12 week trial. Analyses were on an intention-
to-treat basis. At the 12 week evaluation, 42% of pa-
tients in arm A had erythroid responses compared to
0% of arm B patients (P 5 .01). In arm B there were
no significant changes in transfusion requirements or
mean hemoglobin level from baseline to 12 weeks.
Chemotherapy ± Cytokine Therapy
Zwierzina et al. [87] reported the results of 180 adult
(28-83 years) patients with MDS in a multicenter, ran-
domized controlled study comparing low-dose cytosine
arabinoside (AraC) alone (armA, n5 59) or in combina-tionwithGM-CSF(armB,n5 59) or Interleukin-3 (IL-
3) (armC, n5 62).Complete, partial, orminor response
was achieved in 44.1%, 33.9%, and 40.3% of arms A, B,
and C, respectively (P5 .52). At a median follow-up of
3.7 years, OS was 18.7%, 14.7%, and 20.2% (P 5 .60)
and PFS was 8.9%, 7.8%, and 13.0% (P 5 .27) in
arms A, B, and C, respectively. Treatment related mor-
tality was 8.2%, 10.0%, and 7.9% in arms A, B, and C,
respectively (P not stated).
Verbeek et al. [88] presented the outcomes of 29
adult (20-73 years) patients with high-risk MDS in
a prospective, multicenter, randomized, double-blind,
placebo-controlled study comparing the efficacy of
high-dose AraC and mitoxantrone chemotherapy
plus GM-CSF (n5 16) or placebo (n5 13). Complete
remission was achieved in 34.5% and 38% (P 5 .49)
and treatment-related mortality was 44% and 23%
(P 5 .22) in the GM-CSF and placebo arms, respec-
tively.
Hypomethylating Agents
Decitabine
Kantarjian et al. [89] presented the results of a mul-
ticenter, randomized controlled trial investigating the
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supportive care (n 5 81) alone in 170 adult (62-76
years) patients with MDS. Supportive care included
red blood cell and platelet transfusion as needed. In
an intention-to-treat analysis, overall response rate
was higher in the decitabine group compared to the
supportive care only group (17% versus 0%, P \
.001). Median survival was not significantly different
between the decitabine and supportive care groups
(14.0 versus 14.9 months, P 5.636).
Azacitidine
Silverman et al. [90] reported the results of 191
adult (31-92 years) patients withMDS in amulticenter,
randomized controlled study comparing the efficacy of
subcutaneous azacitidine-C (Aza C, n 5 99) to sup-
portive care alone (n 5 92). Both groups received
transfusions and antibiotics as needed. In an inten-
tion-to-treat analysis, 23% of Aza C and 0% of sup-
portive care patients achieved complete or partial
remission (P \ .0001). Of the Aza C patients, 37%
met the criteria for hematologic improvement com-
pared to 5% of the supportive care patients (P \
.0001). The median time to AML or death was 12
months for supportive care compared to 21 months
for the azacitidine group (P 5 .007). For high-risk
FAB subtypes (RAEB, RAEB-t, CMML), the median
time to AML or death was 8 months for supportive
care versus 19 months for the azacitidine group (P 5
.004). AML transformation as the first event occurred
in 38% of the supportive care group compared to 15%
of the azacitidine group (P 5 .001). Crossover from
supportive care to azacitidine was allowed, and a sub-
group analysis suggested that early azacitidine treat-
ment may improve survival.
Immunomodulating Agents
This section includes Phase II studies, because
Phase III studies and meta-analyses are lacking.
Thalidomide
Raza et al. [91] reported the outcomes of 83 adult
(median age, 67 years) patients with MDS enrolled in
a single center, nonrandomized pilot study of the effi-
cacy of thalidomide. Patients were given a daily dose of
100-400 mg orally, as tolerated. Fifty-one patients
completed the minimum period for response evalua-
tion of 12 weeks, whereas 32 went off study prior to
12 weeks because of disease progression (n5 6), other
medical problems (n 5 11), or drug side effects (n 5
14). Analysis was on an intention-to-treat basis, with
all off-study patients being classified as nonresponders.
Sixteen patients (31%) showed hematologic improve-
ment; no complete remissions were achieved.
Strupp et al. [92] presented the results of 34 adult
(54-83 years) patients with MDS in a single center,nonrandomized pilot study of thalidomide. Patients
received a 100 mg dose, which was increased every
week by 100 mg until hematologic improvement was
achieved or adverse events occurred. The dose was
continued until no further improvement was noted,
then gradually decreased as long as peripheral blood
counts were maintained. At a median follow-up of 13
months, 4 patients discontinued treatment because of
side effects, 1 died, 6 showed progressive disease (in-
cluding 5 with AML transformation), 4 had stable dis-
ease, and 19 (56%) showed hematologic improvement;
none achieved complete response.
Lenalidomide
List et al. [93] reported the outcomes of 43 adult
(28-85 years) patients with MDS treated in a single
center, nonrandomized study of the safety and efficacy
of lenalidomide. Patients received 25 mg daily (n5 13,
arm A), 10 mg daily (n5 13, arm B), or 10 mg daily for
21 days of every 28-day cycle (arm C, n5 17). Adverse
effects resulted in decreased dosing or interruption of
treatment in 25 (58%) patients. Response to treatment
was assessed at 16 weeks. Twenty-four (56%) patients
had a hematologic response, including 20 with sus-
tained transfusion independence.
List et al. [94] presented the results of a multicen-
ter study to determine the efficacy of lenalidomide in
reducing transfusion dependence in 148 adult (37-95
years) MDS patients with chromosome 5q deletion.
Forty-six patients received 10 mg of lenalidomide
daily for 21 of a 28-day cycle, and 102 received
continuous daily dosing. Patients were assessed for
response after 24 weeks of treatment by an inten-
tion-to-treat analysis. Of 148 patients, 112 (76%) re-
sponded to treatment, with 99 achieving transfusion
independence and 13 patients achieving a .50% re-
duction in transfusion need. There was no significant
difference in response rate between the two treatment
schedules (P 5 .26). At a median follow-up of 104
weeks, 53 patients remained transfusion independent.
Of 85 patients for whom baseline and week 24 cyto-
genetic data were available, 38 (45%) had a complete
cytogenetic remission and 24 (28%) had a partial cy-
togenetic response.
Raza et al. [95] reported the results of 214 adult
(27-94 years) patients enrolled in a multicenter trial
of the efficacy of lenalidomide in the treatment of
transfusion-dependent, low- or intermediate-1-risk
MDS with karyotypes other than chromosome 5q de-
letion. Patients received 10mg lenalidomide daily (n5
100) or for 21 days of a 28-day cycle (n 5 114). In an
intention-to-treat analysis, 56 (26%) patients achieved
transfusion independence after a median 4.8 weeks of
treatment, which was maintained at a median of 41
weeks. An additional 37 patients achieved a $50% re-
duction in transfusions, yielding a 43% overall rate of
hematologic improvement.
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Raza et al. [96] presented the outcomes of 37 adult
(median age, 68 years) patients in a single-center trial
evaluating the efficacy of treatment with infliximab,
a chimericmonoclonal antibody, in low-riskMDS. Pa-
tients received either 5 (n 5 18) or 10 (n 5 19) mg/kg
of infliximab intravenously every 4 weeks for 4 cycles.
Of 37 patients, 27 were able to complete all 4 cycles,
whereas 10 discontinued therapy because of disease
progression or adverse effects. In an intention-to-treat
analysis, there were 8 (21.6%) responders, 3 from the 5
mg/kg cohort and 5 from the 10 mg/kg cohort. Two
patients achieved transfusion independence and two
patients had a .50% reduction in transfusions.
QUALITYOF LIFE
This section provides information on common
symptoms of MDS that influence patient quality of
life, as well as several studies of treatment effectiveness
in improving the quality of life for MDS patients. The
data in this table are provided for the reader’s informa-
tion and were not used to make treatment recommen-
dations.
MDS Symptoms and Quality of Life
Steensma et al. [97] reported the results of 359
adult (20-90 years) patients withMDS in a multicenter
study examining MDS-associated symptom burden
and the correlation of these symptoms with specific
disease variables, such as hemoglobin level. A
120-item Internet-based survey incorporated several
validated quality of life measurement instruments,
including the Charlson Co-Morbidity Index, the Brief
Fatigue Inventory (BFI), the Functional Assessment of
Cancer Therapy-Anemia (FACT-An) Scale, and the
Godin Leisure Time Activity Score, as well as pa-
tient-reported demographic and disease-specific infor-
mation and most recent blood counts. Fatigue was the
most commonly reported symptom (89%), followed
by bruising/bleeding (55%), night sweats (43%),
bone pain (39%), fevers (28%), skin rash (25%), unde-
sired weight loss (25%), and recurrent infections
(20%). Fatigue was associated with impairment of
health-related quality of life and ability to work or en-
gage in desired activities. Patient mean scores on qual-
ity of life measures were significantly worse than the
published norms (controls) obtained by administering
the BFI to 290 healthy persons and the FACT-An to
1400 members of the general population. Means of
50.5 and 77.1 (P\ .0001) on the FACT-An (where
‘‘100’’ is the best result) and 5.8 and 2.2 (P\ .0001)
on the BFI (where ‘‘0’’ is the best result) were obtained
for patients and controls, respectively. There was no
correlation between BFI or FACT-An scores andpatient-reported hemoglobin level or transfusion
requirement.
Jansen et al. [98] presented a multicenter study in-
vestigating the association between severity of chronic
anemia and health-related quality of life in 50 adult
(49-93 years) patients with MDS. Hemoglobin level
was measured during an outpatient visit, and patients
completed a questionnaire consisting of the Short
Form 36, the Multidimensional Fatigue Inventory,
and the EuroQOL-5D Visual Analog Scale within 24
hours. Median scores on the three scales were worse
for MDS patients than for controls of similar age and
sex from the general population, specifically on physi-
cal functioning, role physical, and physical sum score
on the Short Form-36 and the physical fatigue score
on the Multidimensional Fatigue Inventory. There
were significant correlations between hemoglobin
level and the Visual Analog Scale score (P 5 .05), the
dimensions of physical functioning (P \ .001), role
physical (P 5 .02), vitality (P 5 .02), and physical
sum score (P 5 .01) on the Short Form-36, and the
physical fatigue (P 5 .03) and reduced activity (P 5
.02) scores on theMultidimensional Fatigue Inventory.
Effect of Treatment for MDS on Quality of Life
Epoetin 6 G-CSF
The Casadevall et al. [86] study described previ-
ously in this review examined the impact of treatment
with rHuEpo 1 rHuG-CSF on the quality of life of
MDS patients. A validated French version of the
FACT-An questionnaire was administered to the
treatment and control (supportive care only) groups
at baseline and weeks 12, 28, and 52 to measure four
general domains of quality of life: physical, social/fam-
ily, emotional, and functional well-being. The baseline
questionnaire was completed by 96.7% and 93.3% of
patients in the treatment and control groups, respec-
tively, with a completion rate of 50.0% and 66.7%
by week 52. Total FACT-An, anemia, and fatigue
scores were similar for the two groups at baseline
and throughout the study, indicating no significant ef-
fect of treatment with rHuEpo1 rHuG-CSF on qual-
ity of life.
Spiriti et al. [99] examined the impact of patient re-
sponse to treatment with epoetin alpha on quality of
life and fatigue in 133 adult (37-92 years) low-risk
MDS patients enrolled in a prospective, noncon-
trolled, multicenter study. The FACT-An question-
naire was administered at baseline (n 5 103, 77%),
week 4 (n5 97, 73%), and week 8 (n5 86, 65%) after
start of epoetin alpha treatment. FACT-An score
changes from baseline were positively associated with
hemoglobin changes at week 4 (P 5 .07) and week 8
(P 5 .01). The mean FACT-An scores increased
from baseline to week 8 by 110.2 and 15.6 points in
responders and nonresponders, respectively.
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Stasi et al. [100] reported the results of a multicen-
ter, noncontrolled study of the impact of response to
darbepoetin alfa on the quality of life of 53 adult (59-
82 years) patients with low- and intermediate-1-risk
MDS. Patients received a 150-mg fixed dose of darbe-
poetin alfa administered subcutaneously once a week
for 24 weeks. Quality of life was assessed using the Lin-
ear Analog Scale Assessment and FACT-An. Forty-
eight patients (90%) completed 24 weeks of treatment,
with an erythroid response of 45% (95% CI 31%-
59%). There was a mean increase in Linear Analog
Scale Assessment and FACT-An scores for hemoglo-
bin responders, whereas nonresponders had a mean
decrease in quality of life scores. Hemoglobin level
was significantly related to improved quality of life
scores on FACT-An (P 5 .025) and to energy level
(P 5 .036), daily activities (P 5 .001), and overall
well-being (P 5 .024) on the Linear Analog Scale As-
sessment.
Azacitidine
Kornblith et al. [101] and Silverman et al. [90] re-
ported the results of 191 adult (30-801 years) MDS
patients in a randomized, multicenter Cancer and Leu-
kemia Group B (CALGB) trial assessing the impact of
treatment with Aza C (75 mg/m2 subcutaneous for 7
days every 4 weeks) versus supportive care on quality
of life. A questionnaire consisting of the EORTC
QOL and the Mental Health Inventory was adminis-
tered to patients by standard telephone interview be-
fore randomization and on days 50, 106, and 182
after start of Aza C. Patients treated with Aza C
showed significant improvements in fatigue (EORTC,
P 5 .001), physical functioning (EORTC, P 5 .002),
dyspnea (EORTC, P 5 .0014), psychosocial distress
(Mental Health Inventory, P5 .0015), and positive af-
fect (Mental Health Inventory, P 5 .0077) compared
to the supportive care group.
FUTURE DIRECTIONS
Areas of Needed Research
After reviewing the evidence, the expert panel
identified the following important areas of needed re-
search in MDS:
1. The benefit of using alternative donor sources (eg,
cord blood; haploidentical family donors) for pa-
tients without matched sibling or unrelated donors.
2. The role and appropriate timing of allogeneic SCT
in combination with hypomethylating and immu-
nomodulatory treatment regimens.
3. Randomized trials comparing the safety and effi-
cacy of various novel agents for treating MDS.4. The influence of the various MDS treatment mo-
dalities on patient-reported quality of life out-
comes.
Ongoing Studies
Several studies are summarized below that address
areas of needed research or other issues that may affect
the treatment recommendations made in Table 3.
These studies are currently accruing patients, are on-
going, or have been published in abstract form.
Alternative donor sources
Takahashi et al. [102] evaluated the safety and effi-
cacy of unrelated bone marrow transplantation (n 5
532) versus unrelated cord blood transplantation (n 5
433) in a single-center study of 965 patients with
MDS or secondary AML treated between 1993 and
2006. Compared with bone marrow recipients, cord
blood recipients were older (median age, 52 versus 39
years), included more secondary AML patients (58%
versus 38%), andweremore likely to have received a re-
duced intensity regimen (55% versus 18%). Median
follow-up was 21 and 12 months for bone marrow
and cord blood transplantation, respectively. TRM
(25% versus 38% at 1 year, P\ .01), relapse (15% ver-
sus 26% at 3 years, P\.01), andDFS (57%versus 29%
at 3 years, P\ .01) were better for bone marrow com-
pared with cord blood transplantation, respectively.
The National Heart, Lung, and Blood Institute
(NHLBI) has sponsored a Phase III, randomized, mul-
ticenter, prospective study (BMT CTN-0501) of sin-
gle versus double cord blood transplantation in
pediatric (2-21 years) patients with hematologic malig-
nancies, including MDS at any stage. Overall survival
will be measured one year after study entry, and pa-
tients will be followed for at least 24 months posttrans-
plantation.
The NHLBI and the National Cancer Institute
have sponsored a Phase III, randomized, multicenter,
prospective study (BMT-CTN 0201) of G-CSF-mo-
bilized peripheral blood stem cells versus bonemarrow
from unrelated donors for allogeneic transplantation
in patients up to 66 years of age with hematologic dis-
eases, including MDS. Patients will be randomized to
either the peripheral blood or bone marrow group in
a 1:1 ratio, and will be stratified by transplantation cen-
ter and disease risk. Two-year OS is the primary out-
come measure.
Transplantation techniques
The FHCRC has sponsored a Phase III, random-
ized, multicenter, prospective study comparingmyeloa-
blative (fludarabine1 busulfan or cyclophosphamide1
busulfan) versus nonmyeloablative (fludarabine 1 low-
dose TBI) conditioning regimens for 270 patients
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peripheral blood stem cell transplantation. Two-year
OS is theprimaryoutcomemeasure, andpatients are fol-
lowed for 5 years.
The Southwest Oncology Group (SWOG) has
sponsored a Phase III, randomized, multicenter, pro-
spective study (SWOG-S9920) comparing busulfan
1 TBI versus cyclophosphamide 1 TBI conditioning
regimens for 240 patients (16-55 years) with MDS or
secondary AML undergoing HLA-identical sibling
peripheral blood stem cell transplantation. Patients
are stratified by disease, age, and IPSS risk group.
EFS is the primary outcome measure.
Transplantation in older patients
The Center for International Blood and Marrow
Transplant Research (CIBMTR) has sponsored a mul-
ticenter study evaluating patient, disease, and treat-
ment factors in relation to transplantation outcomes
in older (40-651 years) patients. A total of 6632 pa-
tients with MDS (n 5 1491), AML (n 5 1613),
CML (n5 2590), or diffuse or follicular non-Hodgkin
lymphoma (NHL) (n 5 938), who received allogeneic
stem cell transplantation from an HLA-identical sib-
ling or unrelated donor and were reported to the
CIBMTR between 1995 and 2005, are included in
the analysis. Patients are stratified by disease and age.
DFS and OS are primary outcome measures.
Novel agent versus supportive care
Passweg et al. [103] reported the results of a Phase
III, randomized, multicenter, prospective study (SWS-
SAKK-33/99) comparing the outcomes for 88 patients
(23-75 years) with MDS treated with antithymocyte
globulin1 cyclosporine (ATG1 CSA, n5 45) versus
best supportive care (BSC, n 5 43) between 2001 and
2006. Patients with CMML, RAEB-t, or treatment-re-
lated MDS were excluded from the trial. Patients were
stratified by treatment center and IPSS risk score. At 6
months, 13 versus 5 patients had a hematologic re-
sponse in the ATG 1 CSA and BSC groups, respec-
tively (P 5 .04). Two-year OS was 49% in the ATG
1 CSA group versus 61% in the BSC group (P5 .90).
STRENGTHS/LIMITATIONS AND
DISCUSSION
The strengths of this systematic evidence-based re-
view are the details conveyed in the text about each
study’s design, the presentation of outcomes in sum-
mary tables for each major section, and the treatment
recommendations made by the MDS expert panel. A
limitation is the exclusion of nonpeer-reviewed data.
Unpublished data can represent ‘‘negative’’ findings,
which could lead to publication bias; however, the
inclusion of high-quality, peer-reviewed publicly avail-able data was of paramount importance. Data pub-
lished in abstract form were not included because of
the inadequate details of study design or patient char-
acteristics, making a true assessment of the widespread
applicability or impact of the treatment outside the
scope of the trial difficult.
A limitation of the studies included in this review is
the lack of comparative trials of SCT versus non-SCT
options. Because allogeneic SCT is the only curative
option, patients with an available donor receive an al-
logeneic SCT, making randomized trials uncommon.
However, the BMT-CTN provides a framework for
conducting multicenter BMT trials that can address
some of the areas of needed research in MDS.
The quality of this systematic evidence-based re-
view is affected by treatment modalities that vary
over time. Chemotherapy regimens, HLA typing tech-
niques, pre-SCT treatment regimens, stem cell sour-
ces, and post-SCT supportive care have changed and
progressed considerably over the 18 years of studies in-
cluded in this review. The clinical research process is
lengthy, making data from many of these studies out-
moded by the time of publication.
Many studies included in this evidence-based re-
view combined patients with de novoMDS, therapy-re-
lated MDS, and secondary AML (AML arising from
MDS) in their study population. Because these three
conditions have prognostic value on treatment out-
comes, results should be stratified by disease and dis-
ease etiology (de novo versus secondary).
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